<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Cefepime: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Cefepime: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Cefepime: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="9215" href="/d/html/9215.html" rel="external">see "Cefepime: Drug information"</a> and <a class="drug drug_patient" data-topicid="11316" href="/d/html/11316.html" rel="external">see "Cefepime: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F20452476"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Maxipime [DSC]</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52866233"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>APO-Cefepime</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1045931"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antibiotic, Cephalosporin (Fourth Generation)</span></li></ul></div>
<div class="block don drugH1Div" id="F53462396"><span class="drugH1">Dosing: Neonatal</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>General dosing, susceptible infection:</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">Age-directed dosing (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15980347','lexi-content-ref-AAP.2','lexi-content-ref-26810655','lexi-content-ref-32116695']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15980347','lexi-content-ref-AAP.2','lexi-content-ref-26810655','lexi-content-ref-32116695'])">Ref</a></span>): <b>Note: </b>Dosing based on pharmacokinetic evaluations and modeling from neonates and young infants, including patients with GA ranging from 22 to 42 weeks.</p>
<p style="text-indent:-2em;margin-left:6em;">Preterm and term neonates: IV:</p>
<table border="1" frame="border" rules="all" style="margin-left:8em;">
<colgroup><col align="left"/>
<col align="left"/>
</colgroup><thead valign="top">
<tr>
<th align="left">
<p style="text-indent:0em;">
<b>Postnatal Age</b></p></th>
<th align="left">
<p style="text-indent:0em;">
<b>Dose</b></p></th></tr></thead>
<tfoot valign="top">
<tr>
<td align="left" colspan="2">
<p style="text-indent:0em;">
<sup>a</sup> Consider dosing at the lower end of the range in less mature patients (including PNA &lt;14 days) and/or for more susceptible pathogens (ie, minimum inhibitory concentration [MIC] &lt;4 mg/L).</p>
<p style="text-indent:0em;">
<sup>b</sup> If pathogen MIC is ≥8 mg/L, doses may need to be infused over 3 hours or frequency increased to every 6 hours to achieve desired time &gt; MIC.</p></td></tr></tfoot>
<tbody valign="top">
<tr>
<td align="left">
<p style="text-indent:0em;">&lt;30 days</p></td>
<td align="left">
<p style="text-indent:0em;">30 to 50 mg/kg/dose every 12 hours<sup>a</sup></p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">≥30 days</p></td>
<td align="left">
<p style="text-indent:0em;">50 mg/kg/dose every 8 hours<sup>b</sup></p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Weight-directed dosing (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bradley.3']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bradley.3'])">Ref</a></span>): IV, IM:</p>
<table border="1" frame="border" rules="all" style="margin-left:6em;">
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;">Body Weight</p></th>
<th align="center">
<p style="text-indent:0em;">Postnatal Age</p></th>
<th align="center">
<p style="text-indent:0em;">Dose</p></th></tr></thead>
<tfoot>
<tr>
<td align="center" colspan="3">
<p style="text-indent:0em;text-align:left;">
<sup>a</sup>If pathogen MIC is ≥8 mg/L, doses may need to be infused over 3 hours or frequency increased to every 6 hours.</p></td></tr></tfoot>
<tbody>
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;">≤2 kg</p></td>
<td align="center">
<p style="text-indent:0em;">≤28 days</p></td>
<td align="center">
<p style="text-indent:0em;">30 mg/kg/dose every 12 hours</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">29 to 60 days</p></td>
<td align="center">
<p style="text-indent:0em;">50 mg/kg/dose every 8 hours<sup>a</sup></p></td></tr>
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;">&gt;2 kg</p></td>
<td align="center">
<p style="text-indent:0em;">≤28 days</p></td>
<td align="center">
<p style="text-indent:0em;">50 mg/kg/dose every 12 hours</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">29 to 60 days</p></td>
<td align="center">
<p style="text-indent:0em;">50 mg/kg/dose every 8 hours<sup>a</sup></p></td></tr></tbody></table></div>
<div class="block dop drugH1Div" id="F147337"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>General dosing, susceptible infection:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Traditional intermittent-infusion method</i>: Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">Non-<i>Pseudomonas</i> spp. infections: IM, IV: 50 mg/kg/dose every 12 hours; maximum dose: 2,000 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-AAP.1'])">Ref</a></span>). <b>Note:</b> Every-12-hour dosing may be suboptimal for infections caused by bacteria with minimum inhibitory concentrations (MICs) ≥1 mg/L based on pharmacokinetic modeling (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19422028','lexi-content-ref-26810655']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19422028','lexi-content-ref-26810655'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i> Pseudomonas</i> spp. infections (suspected or proven): IM, IV: 50 mg/kg/dose every 8 hours; maximum dose: 2,000 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-AAP.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Extended-infusion method: </i>Limited data available: Infants, Children, and Adolescents: IV: 50 mg/kg/dose infused over 3 to 4 hours every 8 hours; maximum dose: 2,000 mg/dose; dosing based on a pharmacokinetic modeling study, a case series, and a retrospective comparative study (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Beauchamp.1','lexi-content-ref-25614528','lexi-content-ref-26810655']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Beauchamp.1','lexi-content-ref-25614528','lexi-content-ref-26810655'])">Ref</a></span>). <b>Note</b>: Extended-infusion dosing may be preferred for susceptible dose-dependent pathogens (MIC of 4 or 8 mg/L) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-AAP.1','lexi-content-ref-26810655']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-AAP.1','lexi-content-ref-26810655'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1d1d4c54-ef98-486f-9c71-c0e9856532b2">Cystic fibrosis, acute pulmonary exacerbation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cystic fibrosis, acute pulmonary exacerbation:</b> Infants, Children, and Adolescents: IV: 50 mg/kg/dose every 8 hours; maximum dose: 2,000 mg/dose; patients with more resistant pseudomonal isolates (MIC ≥16 mg/L) may require 50 mg/kg/dose every 6 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22949297']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22949297'])">Ref</a></span>). <b>Note:</b> Some experts prefer extended or continuous infusion methods to optimize antipseudomonal beta-lactam exposure in patients with cystic fibrosis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16533828','lexi-content-ref-26498903','lexi-content-ref-22346306','lexi-content-ref-27132188']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16533828','lexi-content-ref-26498903','lexi-content-ref-22346306','lexi-content-ref-27132188'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5f604944-1182-4061-a5ff-e4371f88c6b6">Endocarditis, prosthetic valve, treatment within 1 year of replacement</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Endocarditis, prosthetic valve, treatment within 1 year of replacement:</b> Children and Adolescents: IV: 50 mg/kg/dose every 8 to 12 hours in combination with vancomycin and rifampin for 6 weeks plus gentamicin for the first 2 weeks; maximum dose: 2,000 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26373317']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26373317'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2c793dec-5eab-4546-a35b-77e4454a2e01">Febrile neutropenia, empiric therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Febrile neutropenia, empiric therapy:</b> Infants, Children, and Adolescents: IV: 50 mg/kg/dose every 8 hours; maximum dose: 2,000 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-AAP.1'])">Ref</a></span>); duration of therapy dependent upon febrile neutropenia risk-status; in high-risk patients, may discontinue empiric antibiotics if all of the following criteria met: Negative blood cultures at 48 hours; afebrile for at least 24 hours, and evidence of marrow recovery. In low-risk patients, may discontinue empiric antibiotics after 72 hours duration in patients with a negative blood culture and who have been afebrile for 24 hours regardless of marrow recovery status; follow-up closely (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28459614']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28459614'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="02b4604f-7121-4a88-88dd-a5008cafb941">Intra-abdominal infection, complicated</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Intra-abdominal infection, complicated:</b> Infants, Children, and Adolescents: IV: 50 mg/kg/dose every 12 hours in combination with metronidazole; maximum dose: 2,000 mg/dose. <b>Note:</b> IDSA guidelines recommend duration of 4 to 7 days (provided source controlled) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20034345']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20034345'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="63a1da04-9672-40b9-bbfe-cb4d46354a2e">Meningitis, including health care-associated ventriculitis/meningitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Meningitis, </b>
<b>including health care-associated ventriculitis/meningitis<b>:</b></b> Infants, Children, and Adolescents: IV: 50 mg/kg/dose every 8 hours; maximum dose: 2,000 mg/dose. Duration should be individualized based on patient characteristics and response; treatment duration for gram-negative bacilli is a minimum of 10 to 14 days, although some experts recommend ≥21 days and at least 14 days after first negative cerebrospinal fluid culture (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15494903','lexi-content-ref-28203777']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15494903','lexi-content-ref-28203777'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1762e085-16eb-4d56-91f6-48f0c61ce809">Peritonitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritonitis (peritoneal dialysis)</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22851742']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22851742'])">Ref</a></span>): Infants, Children, and Adolescents: Intraperitoneal:</p>
<p style="text-indent:-2em;margin-left:4em;">Intermittent: 15 mg/kg/dose every 24 hours into the long dwell.</p>
<p style="text-indent:-2em;margin-left:4em;">Continuous: Loading dose: 500 mg per liter of dialysate; maintenance dose: 125 mg per liter.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8b267629-a1f9-4b4c-a9d5-296e626657aa">Pneumonia, moderate to severe</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pneumonia, moderate to severe:</b> Infants ≥2 months, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:4em;">Due to <i>P. aeruginosa:</i> IV: 50 mg/kg/dose every 8 hours for 10 days; maximum dose: 2,000 mg/dose.</p>
<p style="text-indent:-2em;margin-left:4em;">Not due to P. <i>aeruginosa: </i>IV: 50 mg/kg/dose every 12 hours for 10 days; maximum dose: 2,000 mg/dose.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f6389141-74ef-4696-bc59-0cba2ce00f38">Skin and skin structure infection, uncomplicated</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Skin and skin structure infection, uncomplicated:</b> Infants ≥2 months, Children, and Adolescents: IV: 50 mg/kg/dose every 12 hours for 10 days; maximum dose: 2,000 mg/dose.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c020ef5b-5e07-4086-aca8-907e0e1a63fa">Urinary tract infection, complicated and uncomplicated</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Urinary tract infection, complicated and uncomplicated:</b> Infants ≥2 months, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:4em;">Mild to moderate infection: IM, IV: 50 mg/kg/dose every 12 hours for 7 to 10 days; maximum dose: 1,000 mg/dose. <b>Note:</b> IM may only be considered for mild to moderate infections due to <i>E. coli</i>.</p>
<p style="text-indent:-2em;margin-left:4em;">Severe infection: IV: 50 mg/kg/dose every 12 hours for 10 days; maximum dose: 2,000 mg/dose.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51083982"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Dosing is based on pharmacokinetic parameters, limited pediatric studies, adult studies, manufacturer labeling, and expert opinion.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: IV, IM:</p>
<table border="1" frame="border" rules="all" style="margin-left:6em;">
<caption>
<b>Cefepime Dosing Adjustments for Maintenance Dose in Renal Impairment</b></caption>
<colgroup><col/>
<col/>
<col/>
<col/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;">CrCl</p></th>
<th align="left" colspan="3">
<p style="text-indent:0em;text-align:center;">Recommended Dosing Schedule</p></th></tr></thead>
<tfoot>
<tr>
<td align="left" colspan="4">
<p style="text-indent:0em;text-align:left;">
<b>Note:</b> Dosing regimens reflect the similarity in cefepime pharmacokinetics between adult and pediatric patients and are generally proportional to the changes made in adult patients. Based on minimum inhibitory concentrations (MIC) of bacteria, higher doses may be indicated (Shoji 2016).</p>
<p style="text-indent:0em;text-align:left;">
<sup>a</sup> Choose usual recommended dose based on indication and disease severity (see "Dosing: Pediatric"), then choose the adjusted dose from that column corresponding to the patient's CrCl.</p></td></tr></tfoot>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;">&gt;60 mL/minute/1.73 m<sup>2</sup></p>
<p style="text-indent:0em;">(Usual recommended dose)<sup>a</sup></p></td>
<td align="left">
<p style="text-indent:0em;">50 mg/kg/dose every 12 hours; maximum dose: 1,000 mg/dose</p></td>
<td align="left">
<p style="text-indent:0em;">50 mg/kg/dose every 12 hours; maximum dose: 2,000 mg/dose</p></td>
<td align="left">
<p style="text-indent:0em;">50 mg/kg/dose every 8 hours; maximum dose: 2,000 mg/dose</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">30 to 60 mL/minute/1.73 m<sup>2</sup></p></td>
<td align="left">
<p style="text-indent:0em;">50 mg/kg/dose every 24 hours; maximum dose: 1,000 mg/dose</p></td>
<td align="left">
<p style="text-indent:0em;">50 mg/kg/dose every 24 hours; maximum dose: 2,000 mg/dose</p></td>
<td align="left">
<p style="text-indent:0em;">50 mg/kg/dose every 12 hours; maximum dose: 2,000 mg/dose</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">11 to 29 mL/minute/1.73 m<sup>2</sup></p></td>
<td align="left">
<p style="text-indent:0em;">25 mg/kg/dose every 24 hours; maximum dose: 500 mg/dose</p></td>
<td align="left">
<p style="text-indent:0em;">25 to 50 mg/kg/dose every 24 hours; maximum dose: 1,000 mg/dose</p></td>
<td align="left">
<p style="text-indent:0em;">50 mg/kg/dose every 24 hours; maximum dose: 2,000 mg/dose</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">&lt;11 mL/minute/1.73 m<sup>2</sup></p></td>
<td align="left">
<p style="text-indent:0em;">25 mg/kg/dose every 24 hours; maximum dose: 250 mg/dose</p></td>
<td align="left">
<p style="text-indent:0em;">25 to 50 mg/kg/dose every 24 hours; maximum dose: 500 mg/dose</p></td>
<td align="left">
<p style="text-indent:0em;">25 to 50 mg/kg/dose every 24 hours; maximum dose: 1,000 mg/dose</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent:</b> Dialyzable (based on adult studies: 70% to 85% reduction in serum concentration from a 3.5- to 4-hour hemodialysis treatment with high flux filters (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26846675','lexi-content-ref-10853879']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26846675','lexi-content-ref-10853879'])">Ref</a></span>)).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Appropriate dosing requires consideration of drug penetration to site of infection, MIC of bacteria, severity of illness, residual kidney function, interval between dialysis sessions, receipt of any initial loading doses, etc. Monitor closely for response and adverse reactions due to drug accumulation (eg, neurotoxicity) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29225828']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29225828'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: IV or via dialysis circuit return line:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Intermittent (posthemodialysis) dosing:</i> 50 mg/kg/dose following dialysis; maximum dose: 2,000 mg/dose. <b>Note</b>: Regimen based on 3 to 4 hour dialysis sessions at least 3 times per week. For pediatric patients receiving &lt;3 hours of hemodialysis, consider further dose reduction (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10853879']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10853879'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Daily dosing (when scheduled dose falls on a dialysis day, administer after dialysis):</i> Initial (day 1): 50 mg/kg (maximum dose: 1,000 mg/dose) followed by 12.5 to 25 mg/kg/dose once daily. <b>Note:</b> Maintenance and maximum doses are determined based on the usual recommended dose for patient-specific clinical scenario; recommended doses are as follows: If usual recommended dose is 50 mg/kg/dose every 8 hours, use 25 mg/kg/dose (maximum dose: 1,000 mg/dose) once daily; if usual recommended dose is 50 mg/kg/dose every 12 hours, use 12.5 mg/kg/dose (maximum dose: 500 mg/dose) once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29225828','lexi-content-ref-16945055','lexi-content-ref-manufacturer.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29225828','lexi-content-ref-16945055','lexi-content-ref-manufacturer.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis (manual or automated): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Appropriate dosing requires consideration of drug penetration to site of infection, MIC of bacteria, severity of illness, residual kidney function, receipt of any initial loading doses, etc. Monitor closely for response and adverse reactions due to drug accumulation (eg, neurotoxicity) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29225828']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29225828'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: IV, IM: 25 to 50 mg/kg/dose every 48 hours. Usual maximum dose: 1,000 mg/dose; in severe infections or for bacteria with elevated MICs, 2,000 mg/dose maximum may be considered. Alternatively, 25 to 50 mg/kg/dose every 24 hours may be considered for severe infections (eg, septic shock) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1622165','lexi-content-ref-16945055','lexi-content-ref-manufacturer.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1622165','lexi-content-ref-16945055','lexi-content-ref-manufacturer.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Drug clearance is dependent on the effluent flow rate, filter type, and method of renal replacement. Recommendations are based on high-flux dialyzers and effluent flow rates of ~2,000 mL/hour/1.73 m<sup>2</sup> unless otherwise noted. Appropriate dosing requires consideration of drug penetration to site of infection, MIC of bacteria, severity of illness, receipt of any initial loading doses, etc. Monitor closely for response and adverse reactions due to drug accumulation (eg, neurotoxicity) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29225828']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29225828'])">Ref</a></span>). Due to minimal data in pediatric patients receiving CRRT, consider monitoring serum concentrations (eg, trough concentration) if available.</p>
<p style="text-indent:-2em;margin-left:6em;">CVVH/CVVHD/CVVHDF: IV: 50 mg/kg/dose (maximum dose: 2,000 mg/dose) every 8 to 12 hours. <b>Note:</b> Adult data suggest that in severe infections or sepsis, the risks/benefits favor dosing on the higher side of the recommended frequency. For higher effluent rates (&gt;2,000 mL/hour/1.73 m<sup>2</sup>), bacteria with higher MICs, or deep-seated infections in severely ill pediatric patients, consider extended infusions or more frequent administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16945055','lexi-content-ref-27082510','lexi-content-ref-30718247']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16945055','lexi-content-ref-27082510','lexi-content-ref-30718247'])">Ref</a></span>).</p></div>
<div class="block dohp drugH1Div" id="F51083983"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">No dosage adjustments necessary.</p></div>
<div class="block doa drugH1Div" id="F147319"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9215" href="/d/html/9215.html" rel="external">see "Cefepime: Drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing:</b> Dosing is presented based on the traditional intermittent infusion method over 30 minutes, unless otherwise specified as the extended-infusion method over 3 to 4 hours or continuous infusion method over 24 hours (off-label methods).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Usual dosage range:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Traditional intermittent infusion method (over 30 minutes):</i>
<b>IV:</b> 1 to 2 g every 8 to 12 hours. For coverage of serious <i>Pseudomonas aeruginosa </i>infections: 2 g every 8 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20038614','lexi-content-ref-20435246','lexi-content-ref-28738848']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20038614','lexi-content-ref-20435246','lexi-content-ref-28738848'])">Ref</a></span>). For infections caused by an organism with a minimum inhibitory concentration (MIC) &lt;4 mg/L, 1 g every 6 hours achieves pharmacodynamic parameters comparable to 2 g every 8 hours; reserve for use in less serious infections (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16945055','lexi-content-ref-16943209','lexi-content-ref-12760858']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16945055','lexi-content-ref-16943209','lexi-content-ref-12760858'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Extended infusion method (off-label method):</i>
<b>IV:</b> 2 g every 8 hours infused over 3 or 4 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23341160','lexi-content-ref-23571547','lexi-content-ref-20435246','lexi-content-ref-19188394','lexi-content-ref-28077047']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23341160','lexi-content-ref-23571547','lexi-content-ref-20435246','lexi-content-ref-19188394','lexi-content-ref-28077047'])">Ref</a></span>); may give first dose over 30 minutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28077047']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28077047'])">Ref</a></span>). The extended infusion method is preferred for treatment of infections caused by AmpC beta-lactamase-producing Enterobacterales (eg, <i>Enterobacter cloacae</i>, <i>Klebsiella aerogenes</i>, <i>Citrobacter freundii</i>); however, cefepime should only be used for these infections when the MIC is ≤2 mcg/mL (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34864936']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34864936'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Continuous </i>
<i>infusion method (off-label method):</i>
<b>IV:</b> 4 to 6 g infused over 24 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26754759','lexi-content-ref-16119511','lexi-content-ref-28668694']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26754759','lexi-content-ref-16119511','lexi-content-ref-28668694'])">Ref</a></span>); may give first dose of 2 g over 30 minutes, especially when rapid attainment of therapeutic drug concentrations (eg, sepsis) is desired (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26754759','lexi-content-ref-34599691']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26754759','lexi-content-ref-34599691'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8f9ec9fd-fc1b-4a1f-868a-eeb97c396e6e">Bloodstream infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Bloodstream infection (gram-negative bacteremia) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Community-acquired infection, without sepsis or septic shock</i>
<i>(<i>immunocompetent host and no infections with P. aeruginosa</i></i>
<i> in prior 3 to 6 months):</i>
<b>IV:</b> 2 g every 12 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Moehring.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Moehring.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Health care–associated infection (including catheter-related infection, infection in immunocompromised hosts, patients with sepsis or septic shock, or for coverage of P. aeruginosa):</i>
<b>IV:</b> 2 g every 8 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19489710','lexi-content-ref-Moehring.1','lexi-content-ref-28738848']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19489710','lexi-content-ref-Moehring.1','lexi-content-ref-28738848'])">Ref</a></span>). <b>Note:</b> For empiric therapy of gram-negative bloodstream infection in patients with sepsis or septic shock and for empiric therapy of <i>P. aeruginosa </i>bloodstream infection in patients with neutropenia or severe burns, some experts recommend giving cefepime with a second gram-negative active agent (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kanj.3','lexi-content-ref-Moehring.1','lexi-content-ref-34599691']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kanj.3','lexi-content-ref-Moehring.1','lexi-content-ref-34599691'])">Ref</a></span>). Some experts also prefer extended or continuous infusion for critical illness or when treating a susceptible organism with an elevated MIC (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Moehring.2','lexi-content-ref-34599691']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Moehring.2','lexi-content-ref-34599691'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Duration of therapy:</i> Usual duration is 7 to 14 days; individualize duration depending on source and extent of infection as well as clinical response. A 7-day duration is recommended for patients with uncomplicated Enterobacteriaceae infection who respond appropriately to antibiotic therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Moehring.1','lexi-content-ref-30535100']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Moehring.1','lexi-content-ref-30535100'])">Ref</a></span>). If neutropenic, extend treatment until afebrile for ≥48 hours and recovery of neutrophils (ANC ≥500 cells/mm<sup>3</sup> and increasing) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21258094']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21258094'])">Ref</a></span>). For <i>P. aeruginosa</i> bacteremia in patients who are neutropenic, some experts treat for a minimum of 14 days and until recovery of neutrophils (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kanj.3']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kanj.3'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1d1d4c54-ef98-486f-9c71-c0e9856532b2">Cystic fibrosis, acute pulmonary exacerbation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cystic fibrosis, acute pulmonary exacerbation (off-label use):</b> For empiric or targeted therapy of <i>P. aeruginosa</i> or other gram-negative bacilli:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 2 g every 8 hours, usually given as part of an appropriate combination regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19729669','lexi-content-ref-22949297']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19729669','lexi-content-ref-22949297'])">Ref</a></span>). <b>Note:</b> Some experts prefer the extended or continuous infusion method to optimize exposure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16533828','lexi-content-ref-Simon.1','lexi-content-ref-27132188']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16533828','lexi-content-ref-Simon.1','lexi-content-ref-27132188'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Duration of therapy:</i> Duration is usually 10 to 14 days depending on clinical response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19729669','lexi-content-ref-34469706']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19729669','lexi-content-ref-34469706'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1d3e4522-e8bc-4496-b3e0-f1fcdd0f13d7">Diabetic foot infection, moderate to severe</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Diabetic foot infection, moderate to severe (off-label use): IV:</b> 2 g every 8 to 12 hours in combination with other appropriate agents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1804010','lexi-content-ref-22619242','lexi-content-ref-26897754','lexi-content-ref-Weintrob.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1804010','lexi-content-ref-22619242','lexi-content-ref-26897754','lexi-content-ref-Weintrob.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Duration of therapy:</i> Duration (which may include oral step-down therapy) is usually 2 to 4 weeks in the absence of osteomyelitis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22619242','lexi-content-ref-Weintrob.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22619242','lexi-content-ref-Weintrob.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1a9704e3-3c04-4560-bf3b-ab333b8ed84b">Intra-abdominal infection, health care–associated or high-risk community-acquired infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Intra-abdominal infection, health care–associated or high-risk community-acquired infection:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>For community-acquired infection, reserve for severe infection or patients at high risk of adverse outcome and/or resistance (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Barshak.1','lexi-content-ref-20034345']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Barshak.1','lexi-content-ref-20034345'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Cholecystitis, acute:</i>
<b>IV:</b> 2 g every 8 to 12 hours; if <i>P. aeruginosa</i> is suspected, use 2 g every 8 hours. Continue for 1 day after gallbladder removal or until clinical resolution in patients managed nonoperatively (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29090866','lexi-content-ref-28085573','lexi-content-ref-20034345','lexi-content-ref-Vollmer.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29090866','lexi-content-ref-28085573','lexi-content-ref-20034345','lexi-content-ref-Vollmer.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Other intra-abdominal infections (eg, cholangitis, appendicitis, diverticulitis, intra-abdominal abscess)</i>:<b> IV:</b> 2 g every 8 to 12 hours in combination with metronidazole, and, when appropriate, other agents; if <i>P. aeruginosa</i> is suspected, use 2 g every 8 hours. Total duration of therapy (which may include transition to oral antibiotics) is 4 to 5 days following adequate source control (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25992746','lexi-content-ref-28085573']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25992746','lexi-content-ref-28085573'])">Ref</a></span>). For diverticulitis or uncomplicated appendicitis managed without intervention, duration is 10 to 14 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Barshak.1','lexi-content-ref-Pemberton.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Barshak.1','lexi-content-ref-Pemberton.1'])">Ref</a></span>); for perforated appendicitis managed with laparoscopic appendectomy, 2 to 4 days may be sufficient (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36669519','lexi-content-ref-25992746']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36669519','lexi-content-ref-25992746'])">Ref</a></span>). <b>Note:</b> For patients who are critically ill or are at high risk for infection with drug-resistant pathogens, some experts favor the extended or continuous infusion method (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Barshak.1','lexi-content-ref-28484510']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Barshak.1','lexi-content-ref-28484510'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="89ceb6d9-1a11-4cf3-be3c-d9863bfad7ac">Intracranial abscess and spinal epidural abscess</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Intracranial abscess (brain abscess, intracranial epidural abscess) and spinal epidural abscess (off-label use): </b>As a component of empiric therapy in patients at risk for <i>P. aeruginosa</i> or another resistant gram-negative bacteria (eg, neurosurgical or immunocompromised patients):</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 2 g every 8 hours as part of an appropriate combination regimen; duration generally ranges from 4 to 8 weeks for brain abscess and spinal epidural abscess and 6 to 8 weeks for intracranial epidural abscess (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29909695','lexi-content-ref-sexton.2019a','lexi-content-ref-sexton.2019b','lexi-content-ref-southwick.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29909695','lexi-content-ref-sexton.2019a','lexi-content-ref-sexton.2019b','lexi-content-ref-southwick.2020'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="90b4bed4-9c84-419c-9067-b0892c7eeb49">Meningitis, bacterial</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Meningitis, bacterial (off-label use): Note: </b>As a component of empiric therapy for health care<i>–</i>associated infections or infections in immunocompromised patients, or as pathogen-specific therapy (eg, gram-negative bacteria, including <i>P. aeruginosa</i>):</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 2 g every 8 hours; for empiric therapy, use in combination with other appropriate agents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15494903','lexi-content-ref-28203777']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15494903','lexi-content-ref-28203777'])">Ref</a></span>). Treatment duration for gram-negative bacilli is a minimum of 10 to 14 days, although some experts recommend ≥21 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Hasbun.1','lexi-content-ref-28203777']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Hasbun.1','lexi-content-ref-28203777'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f14f5ce2-bd10-40b4-9131-53adc589c5db">Neutropenic enterocolitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Neutropenic enterocolitis (typhlitis) (off-label use): IV:</b> 2 g every 8 hours in combination with metronidazole (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21258094','lexi-content-ref-Wong.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21258094','lexi-content-ref-Wong.1'])">Ref</a></span>). In patients who have clinical resolution following neutropenia and who did <b>not</b> have signs of severe disease at the time of diagnosis, the duration of antibiotics is 14 days following recovery from neutropenia; many patients can be switched to an appropriate oral antibiotic regimen once neutropenia has resolved (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Wong.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Wong.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2e55b896-e3d1-46d2-a9b0-f54546c753e2">Neutropenic fever, high-risk cancer patients</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Neutropenic fever, high-risk cancer patients (empiric therapy): Note:</b> High-risk patients are those expected to have an ANC ≤100 cells/mm<sup>3</sup> for &gt;7 days <b>or</b> an ANC ≤100 cells/mm<sup>3</sup> for any expected duration if there are ongoing comorbidities (eg, sepsis, mucositis, significant hepatic or renal dysfunction) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21258094']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21258094'])">Ref</a></span>); some experts use an ANC cutoff of &lt;500 cells/mm<sup>3</sup> to define high-risk patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Wingard.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Wingard.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 2 g every 8 hours until afebrile for ≥48 hours and resolution of neutropenia (ANC ≥500 cells/mm<sup>3</sup> and increasing) or standard duration for the specific infection identified, if longer than the duration of neutropenia. Additional agent(s) may be needed depending on clinical status (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21258094']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21258094'])">Ref</a></span>). Some experts prefer extended or continuous infusions for critical illness (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Moehring.2','lexi-content-ref-34599691','lexi-content-ref-Wingard.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Moehring.2','lexi-content-ref-34599691','lexi-content-ref-Wingard.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3c92ca38-0c20-4ec4-b5f0-113c6ccf7cd2">Osteomyelitis and/or discitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Osteomyelitis and/or discitis (off-label use): IV:</b> 2 g every 8 to 12 hours for ≥6 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26229122','lexi-content-ref-Osmon.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26229122','lexi-content-ref-Osmon.1'])">Ref</a></span>). For empiric therapy, use in combination with other appropriate agents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26229122']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26229122'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c2f0164e-28ab-4d30-b893-da899a8afeac">Peritonitis, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritonitis, treatment (patients receiving peritoneal dialysis) (off-label use):</b> As a component of empiric therapy or as pathogen-directed therapy for gram-negative bacteria (eg, <i>P. aeruginosa</i>):</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note</b>: Intraperitoneal is preferred to IV administration unless the patient shows signs of systemic infection, then IV is preferred (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27282851']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27282851'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Automated peritoneal dialysis (APD): <b>Intraperitoneal:</b> 1 g every 24 hours given in the longest dwell is preferred (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27282851']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27282851'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">CAPD:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Intermittent:</i>
<b>Intraperitoneal:</b> 1 g added to one exchange of dialysis solution every 24 hours (to be given in the longest daily dwell) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27282851']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27282851'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Continuous (with every exchange):</i>
<b>Intraperitoneal:</b> Loading dose: 250 to 500 mg/<b>L</b> of dialysate with first exchange of dialysate. Maintenance dose: 100 to 125 mg/<b>L</b> of dialysate with each subsequent exchange of dialysate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27282851']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27282851'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Consider 25% dose increase in patients on APD or CAPD with significant residual kidney function (urine output &gt;100 mL/day) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29987068','lexi-content-ref-29987069']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29987068','lexi-content-ref-29987069'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7792e77c-7758-4230-a81e-dc7dd3a6acb9">Pneumonia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pneumonia:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>Community-acquired pneumonia:</b></i>For empiric therapy of inpatients at risk of infection with a resistant gram-negative pathogen(s), including <i>P. aeruginosa</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> 2 g every 8 hours as part of an appropriate combination regimen. Total duration (which may include oral step-down therapy) is a minimum of 5 days; a longer course may be required for patients with an immunocompromising condition, severe or complicated infection, or for <i>P. aeruginosa</i> infection. Patients should be clinically stable with normal vital signs prior to discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31573350','lexi-content-ref-32561442']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31573350','lexi-content-ref-32561442'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>Hospital-acquired pneumonia or ventilator-associated pneumonia:</b></i>For empiric therapy (often as part of an appropriate combination regimen) or pathogen-specific therapy of resistant gram-negative pathogen(s), including <i>P. aeruginosa</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> 2 g every 8 hours. Duration of therapy varies based on disease severity and response to therapy; treatment is typically given for 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27418577']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27418577'])">Ref</a></span>). <b>Note:</b> Some experts prefer extended or continuous infusions for critical illness or when treating a susceptible organism with an elevated MIC (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Klompas.1','lexi-content-ref-Moehring.2','lexi-content-ref-34599691']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Klompas.1','lexi-content-ref-Moehring.2','lexi-content-ref-34599691'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="20c7bdf4-2039-48ed-903c-cfc08b5badc6">Prosthetic joint infection, pathogen-specific therapy for gram-negative bacilli</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Prosthetic joint infection, </b>
<b>pathogen-specific therapy for gram-negative bacilli </b>
<b>(off-label use): IV:</b> 2 g every 8 to 12 hours; duration varies but is generally 4 to 6 weeks for patients who undergo resection arthroplasty (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Berbari.1','lexi-content-ref-23223583']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Berbari.1','lexi-content-ref-23223583'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a74533c8-554a-440e-8601-6b5e9cffeae7">Sepsis and septic shock</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Sepsis and septic shock (broad-spectrum empiric coverage, including <i>P. aeruginosa</i>) (off-label use):</b>
<b>IV:</b> 2 g every 8 hours (Alves 2014); use in combination with other appropriate agents when applicable. Initiate therapy as soon as possible and preferably within 1 hour of recognition of sepsis or septic shock. Duration is dependent on underlying source and patient response; short courses are preferred, when appropriate. Consider discontinuation if a noninfectious etiology is identified (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34599691']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34599691'])">Ref</a></span>). Some experts prefer extended or continuous infusions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Moehring.2','lexi-content-ref-34599691']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Moehring.2','lexi-content-ref-34599691'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9357c8a8-bc61-4588-803a-17d7cba42c78">Septic arthritis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Septic arthritis (off-label use):</b> As a component of empiric therapy or pathogen-specific therapy for gram-negative pathogens (including <i>P. aeruginosa</i>): <b>IV:</b> 2 g every 8 to 12 hours; for empiric therapy, use in combination with other appropriate agents. Total treatment duration is 3 to 4 weeks (in the absence of osteomyelitis), including oral step-down therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Goldenberg.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Goldenberg.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5389b037-d8ce-48e2-98b3-f8bb5a208a34">Skin and soft tissue infection, moderate to severe</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Skin and soft tissue infection, moderate to severe:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>For empiric or pathogen-directed therapy in patients with or at risk for gram-negative bacteria resistant to other antibiotics (eg, <i>P. aeruginosa</i>) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8150761','lexi-content-ref-Kanj.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8150761','lexi-content-ref-Kanj.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 2 g every 8 to 12 hours; often used as part of an appropriate combination regimen. Usual duration (including oral step-down therapy) is 5 to 14 days based on severity and clinical response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8150761','lexi-content-ref-24947530','lexi-content-ref-Kanj.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8150761','lexi-content-ref-24947530','lexi-content-ref-Kanj.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c3dbb92e-1e0f-40e8-92cb-d0cf047a674d">Urinary tract infection, complicated</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Urinary tract infection, complicated (pyelonephritis or urinary tract infection with systemic signs/symptoms):</b>
<b>IV:</b> 1 to 2 g every 12 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-manufacturer.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-manufacturer.1'])">Ref</a></span>). Switch to an appropriate oral regimen once symptoms improve if culture and susceptibility results allow. Total duration of therapy ranges from 5 to 14 days and depends on clinical response and the antimicrobial chosen to complete the regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Gupta.1','lexi-content-ref-21292654']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Gupta.1','lexi-content-ref-21292654'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991603"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Altered kidney function:</b> IV:</p>
<table border="1" data-table-id="cefepime" frame="border" rules="all">
<caption style="text-align:left;">
<b>Cefepime Dosage Adjustments in Altered Kidney Function<sup>a</sup></b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead valign="middle">
<tr>
<th align="center">
<p style="text-indent:0em;">CrCl<sup>b</sup></p></th>
<th align="center">
<p style="text-indent:0em;">If the usual recommended dose is 1 g every 12 hours</p></th>
<th align="center">
<p style="text-indent:0em;">If the usual recommended dose is 2 g every 12 hours</p></th>
<th align="center">
<p style="text-indent:0em;">If the usual recommended dose is 1 g every 6 hours</p></th>
<th align="center">
<p style="text-indent:0em;">If the usual recommended dose is 2 g every 8 hours</p></th></tr></thead>
<tfoot>
<tr>
<td align="center" colspan="5">
<p style="text-indent:0em;text-align:left;">
<sup>a </sup>Kuti 2010; Lodise 2006; Tam 2003; manufacturer's labeling.</p></td></tr>
<tr>
<td align="center" colspan="5">
<p style="text-indent:0em;text-align:left;">
<sup>b </sup>CrCl can be calculated using the Cockcroft-Gault equation (Jonckheere 2016).</p></td></tr>
<tr>
<td align="center" colspan="5">
<p style="text-indent:0em;text-align:left;">
<sup>c </sup>Lodise 2006.</p></td></tr>
<tr>
<td align="center" colspan="5">
<p style="text-indent:0em;text-align:left;">
<sup>d </sup>1 g every 12 hours increases the likelihood of pharmacodynamic target attainment and is preferred for serious infections or organisms with less susceptible MICs (Kuti 2010; Tam 2003). Administer a 2 g loading dose when rapid attainment of therapeutic concentrations is desired (expert opinion).</p></td></tr></tfoot>
<tbody valign="middle">
<tr>
<td align="center">
<p style="text-indent:0em;">&gt;60 mL/minute</p></td>
<td align="center">
<p style="text-indent:0em;">No dosage adjustment necessary</p></td>
<td align="center">
<p style="text-indent:0em;">No dosage adjustment necessary</p></td>
<td align="center">
<p style="text-indent:0em;">No dosage adjustment necessary</p></td>
<td align="center">
<p style="text-indent:0em;">No dosage adjustment necessary</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">30 to 60 mL/minute</p></td>
<td align="center">
<p style="text-indent:0em;">1 g every 24 hours</p></td>
<td align="center">
<p style="text-indent:0em;">1 g every 12 hours</p></td>
<td align="center">
<p style="text-indent:0em;">CrCl 50 to 60 mL/minute: No dosage adjustment necessary.</p>
<p style="text-indent:0em;">CrCl 30 to 49 mL/minute: 1 g every 8 hours.<sup>c</sup></p></td>
<td align="center">
<p style="text-indent:0em;">2 g every 12 hours</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">11 to 29 mL/minute</p></td>
<td align="center">
<p style="text-indent:0em;">500 mg every 24 hours</p></td>
<td align="center">
<p style="text-indent:0em;">1 g every 24 hours</p></td>
<td align="center">
<p style="text-indent:0em;">1 g every 12 hours</p></td>
<td align="center">
<p style="text-indent:0em;">1 g every 12 hours<sup>d</sup> or 2 g every 24 hours</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">&lt;11 mL/minute</p></td>
<td align="center">
<p style="text-indent:0em;">250 mg every 24 hours</p></td>
<td align="center">
<p style="text-indent:0em;">500 mg every 24 hours</p></td>
<td align="center">
<p style="text-indent:0em;">1 g every 24 hours</p></td>
<td align="center">
<p style="text-indent:0em;">1 g every 24 hours</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Augmented renal clearance (measured urinary CrCl ≥130 mL/minute/1.73 m<sup>2</sup>):</b> Augmented renal clearance (ARC) is a condition that occurs in certain critically-ill patients without significant organ dysfunction. Younger patients (&lt;55 years of age) admitted post trauma or major surgery are at highest risk for ARC, as well as those with sepsis, burns, or hematological malignancies. A measured urinary clearance is necessary to identify these patients.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Limited data available; dosing based on Monte Carlo simulation and expert opinion.</p>
<p style="text-indent:-2em;margin-left:4em;">IV: Initial: 2 g every 6 hours infused over 3 hours when used empirically or in patients with known minimum inhibitory concentrations (MICs) &gt;4 mg/L (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25381169']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25381169'])">Ref</a></span>). Closely monitor patient for response and adverse reactions (eg, neurotoxicity) due to drug accumulation. Consider obtaining drug concentrations when available.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly): Note: </b>Achievement of cefepime pharmacodynamic targets is dependent on organism MIC, the absence or presence of residual kidney function, and interval between dialysis sessions (ie, 2- or 3-day interdialytic interval) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26846675','lexi-content-ref-22440135','lexi-content-ref-10853879']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26846675','lexi-content-ref-22440135','lexi-content-ref-10853879'])">Ref</a></span>). Factors such as severity of illness, location of infection, and patient weight should be considered when selecting between the higher and lower dosing regimens as well.</p>
<p style="text-indent:-2em;margin-left:4em;">IV: Dialyzable (70% to 85% reduction in serum concentration from a 3.5- to 4-hour hemodialysis treatment with high flux filters (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26846675','lexi-content-ref-10853879']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26846675','lexi-content-ref-10853879'])">Ref</a></span>)).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Daily dosing (administer after hemodialysis on dialysis days):</i> IV: Initial: 1 g (single dose) on day 1. Maintenance: 500 mg to 1 g every 24 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19397464','lexi-content-ref-manufacturer.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19397464','lexi-content-ref-manufacturer.1'])">Ref</a></span>). <b>Note:</b> If the usual recommended dose for normal renal function is 2 g every 8 hours or 1 g every 6 hours, utilize 1 g every 24 hours; use 500 mg every 24 hours for all other doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16945055','lexi-content-ref-manufacturer.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16945055','lexi-content-ref-manufacturer.1'])">Ref</a></span>).</p>
<table border="1" data-table-id="cefepime" frame="border" rules="all">
<caption style="text-align:left;">
<b>Thrice-Weekly (Postdialysis) Cefepime Dosing<sup>a</sup></b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead valign="middle">
<tr>
<th align="center" valign="middle">
<p style="text-indent:0em;">Residual kidney function and organism susceptibility</p></th>
<th align="center">
<p style="text-indent:0em;">
<b>Cefepime dose for a 2-day interdialytic interval (ie, next dialysis expected in 48 hours)</b></p></th>
<th align="center">
<p style="text-indent:0em;">Cefepime dose for a 3-day interdialytic interval (ie, next dialysis expected in 72 hours)</p></th></tr></thead>
<tfoot>
<tr>
<td align="left" colspan="3">
<p style="text-indent:0em;">
<sup>a </sup>Expert opinion derived from Descombes 2016; Perez 2012; Schmaldienst 2000.</p></td></tr></tfoot>
<tbody valign="middle">
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Patient is anuric <b>AND</b> the organism MIC &lt;4 mg/L</p></td>
<td align="center">
<p style="text-indent:0em;">1.5 g after hemodialysis</p></td>
<td align="center">
<p style="text-indent:0em;">2 g after hemodialysis</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">
<b>Any of the following:</b></p>
<p style="text-indent:0em;text-align:left;">Empiric therapy <b>OR</b></p>
<p style="text-indent:0em;text-align:left;">Patient has residual kidney function <b>OR</b></p>
<p style="text-indent:0em;text-align:left;">Organism MIC ≥4 mg/L</p></td>
<td align="center">
<p style="text-indent:0em;">2 g after hemodialysis</p></td>
<td align="center">
<p style="text-indent:0em;">2 g after hemodialysis</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b></p>
<p style="text-indent:-2em;margin-left:4em;">IV: 1 g every 24 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16945055','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16945055','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b> Drug clearance is dependent on the effluent flow rate, filter type, and method of renal replacement. Recommendations are based on high-flux dialyzers and effluent flow rates of 20 to 25 mL/kg/hour (or approximately 1,500 to 3,000 mL/hour) unless otherwise noted. Appropriate dosing requires consideration of adequate drug concentrations (eg, site of infection), organism MIC, residual kidney function, and consideration of initial loading doses. Close monitoring of response and adverse reactions (eg, neurotoxicity) due to drug accumulation is important.</p>
<p style="text-indent:-2em;margin-left:4em;">CVVH/CVVHD/CVVHDF: IV: 2 g every 8 to 12 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24886826','lexi-content-ref-26208469','lexi-content-ref-30221005','lexi-content-ref-31549737','lexi-content-ref-27082510']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24886826','lexi-content-ref-26208469','lexi-content-ref-30221005','lexi-content-ref-31549737','lexi-content-ref-27082510'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> For severe infections or sepsis, the risks/benefits favor dosing on the higher side of the recommended frequency (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27082510']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27082510'])">Ref</a></span>). For CRRT with other effluent rates: If effluent rate is &lt;20 mL/kg/hour, 2 g every 12 hours is preferred (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9371344','lexi-content-ref-11600370']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9371344','lexi-content-ref-11600370'])">Ref</a></span>). If effluent rate is ≥35 mL/kg/hour, 2 g every 8 hours is preferred (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30221005','lexi-content-ref-Droege.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30221005','lexi-content-ref-Droege.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration): </b>Drug clearance is dependent on the effluent flow rate, filter type, and method of renal replacement. Appropriate dosing requires consideration of adequate drug concentrations (eg, site of infection), organism MIC, residual kidney function, and consideration of initial loading doses. Close monitoring of response and adverse reactions (eg, neurotoxicity) due to drug accumulation is important.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Regimens developed through Monte Carlo simulation only and based on daily treatments with 4 to 5 L/hour of dialysate/ultrafiltrate flow rate for each 8- to 10-hour session (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29746711']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29746711'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Option 1:</i> IV: 2 g loading dose, followed by 1 g every 6 hours regardless of when prolonged intermittent renal replacement therapy (PIRRT) treatments occur relative to cefepime infusions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29746711']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29746711'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Option 2 (if every 6 hours not desired [eg, patient self-administering]): </i> IV: 2 g at beginning of PIRRT session, then 3 g after PIRRT session ends. Repeat regimen with every PIRRT session (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29746711']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29746711'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Non-PIRRT days: IV: Select dose based on assessment of nondialysis kidney function (eg, CrCl &lt;11, then 1 g every 24 hours).</p></div>
<div class="block doha drugH1Div" id="F50988823"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">No dosage adjustment necessary. </p></div>
<div class="block arsc drugH1Div" id="F54894368"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Clostridioides difficile infection</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<i>Clostridioides difficile</i> infection (CDI) has been reported with use in adult and pediatric patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33382398','lexi-content-ref-33717772','lexi-content-ref-36921180','lexi-content-ref-31254655']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33382398','lexi-content-ref-33717772','lexi-content-ref-36921180','lexi-content-ref-31254655'])">Ref</a></span>). In one retrospective cohort study, cefepime and meropenem increased CDI risk relative to piperacillin-tazobactam (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33382398']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33382398'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Dose- and time-related; potentially related to recent or cumulative antibiotic exposure. Cefepime may cause disruption of the intestinal microbiota resulting in the overgrowth of pathogens, such as <i>C. difficile</i> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29462280','lexi-content-ref-21653301']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29462280','lexi-content-ref-21653301'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; may start on the first day of antibiotic therapy or up to 3 months postantibiotic (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22146873','lexi-content-ref-29053792']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22146873','lexi-content-ref-29053792'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Antibiotic exposure (highest risk factor) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.2022','lexi-content-ref-29462280','lexi-content-ref-29053792','lexi-content-ref-27216385','lexi-content-ref-29272341']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.2022','lexi-content-ref-29462280','lexi-content-ref-29053792','lexi-content-ref-27216385','lexi-content-ref-29272341'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Type of antibiotic (third-/fourth-generation cephalosporins among the highest risk) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23478961','lexi-content-ref-CDC.2022','lexi-content-ref-24755188','lexi-content-ref-23620467','lexi-content-ref-29053792','lexi-content-ref-29462280','lexi-content-ref-27216385','lexi-content-ref-29272341']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23478961','lexi-content-ref-CDC.2022','lexi-content-ref-24755188','lexi-content-ref-23620467','lexi-content-ref-29053792','lexi-content-ref-29462280','lexi-content-ref-27216385','lexi-content-ref-29272341'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Long durations in a hospital or other health care setting (recent or current) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.2022','lexi-content-ref-29053792','lexi-content-ref-29462280','lexi-content-ref-27216385','lexi-content-ref-29272341']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.2022','lexi-content-ref-29053792','lexi-content-ref-29462280','lexi-content-ref-27216385','lexi-content-ref-29272341'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Older patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.2022','lexi-content-ref-29053792','lexi-content-ref-29462280','lexi-content-ref-27216385','lexi-content-ref-29272341']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.2022','lexi-content-ref-29053792','lexi-content-ref-29462280','lexi-content-ref-27216385','lexi-content-ref-29272341'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Immunocompromised conditions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.2022','lexi-content-ref-29053792','lexi-content-ref-29462280','lexi-content-ref-27216385','lexi-content-ref-29272341']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.2022','lexi-content-ref-29053792','lexi-content-ref-29462280','lexi-content-ref-27216385','lexi-content-ref-29272341'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• A serious underlying condition (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.2022','lexi-content-ref-29053792','lexi-content-ref-29462280','lexi-content-ref-27216385','lexi-content-ref-29272341']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.2022','lexi-content-ref-29053792','lexi-content-ref-29462280','lexi-content-ref-27216385','lexi-content-ref-29272341'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• GI surgery/manipulation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.2022','lexi-content-ref-29462280','lexi-content-ref-27216385']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.2022','lexi-content-ref-29462280','lexi-content-ref-27216385'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Antiulcer medications (eg, proton pump inhibitors, H2 blockers) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29462280','lexi-content-ref-27216385','lexi-content-ref-29272341']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29462280','lexi-content-ref-27216385','lexi-content-ref-29272341'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Chemotherapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29053792','lexi-content-ref-29462280','lexi-content-ref-27216385','lexi-content-ref-29272341']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29053792','lexi-content-ref-29462280','lexi-content-ref-27216385','lexi-content-ref-29272341'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hypersensitivity reactions (immediate and delayed)</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Immediate <b>hypersensitivity reactions</b> (including <b>anaphylaxis</b>, <b>angioedema,</b> and <b>urticaria</b>) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17323865','lexi-content-ref-14763949']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17323865','lexi-content-ref-14763949'])">Ref</a></span>) and delayed hypersensitivity reactions have been reported. Delayed hypersensitivity reactions range from maculopapular <b>skin rash</b> to rare severe cutaneous adverse reactions (SCARs), including <b>acute generalized exanthematous pustulosis</b>, <b>drug reaction with eosinophilia and systemic symptoms</b>, <b>Stevens-Johnson syndrome</b>, and toxic epidermal necrolysis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21103192','lexi-content-ref-26120552','lexi-content-ref-36324356','lexi-content-ref-33097683','lexi-content-ref-28692440','lexi-content-ref-28775112']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21103192','lexi-content-ref-26120552','lexi-content-ref-36324356','lexi-content-ref-33097683','lexi-content-ref-28692440','lexi-content-ref-28775112'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Non–dose-related; immunologic. Immediate hypersensitivity reactions (eg, anaphylaxis, angioedema, urticaria) are IgE-mediated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14763949']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14763949'])">Ref</a></span>). Delayed hypersensitivity reactions, including maculopapular rash and SCARs, are mediated by T-cells (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30558872']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30558872'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Immediate hypersensitivity reactions (eg, anaphylaxis, angioedema, urticaria): Rapid; generally occur within 1 hour of administration but may occur up to 6 hours after exposure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30558872']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30558872'])">Ref</a></span>). Delayed hypersensitivity reactions: Varied; maculopapular reactions typically occur 7 to 10 days after initiation. Other delayed hypersensitivity reactions, including SCARs, may occur 7 to 14 days up to 3 months after initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30558872','lexi-content-ref-26120552','lexi-content-ref-NICE.2014','lexi-content-ref-28775112']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30558872','lexi-content-ref-26120552','lexi-content-ref-NICE.2014','lexi-content-ref-28775112'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Cross-reactivity between penicillins and cephalosporins, and among cephalosporins, is mainly related to side chain similarity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27016799','lexi-content-ref-29408440']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27016799','lexi-content-ref-29408440'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">• Potential cross-reactions may occur between cefepime, ceftriaxone, cefuroxime, ceftazidime, and cefotaxime (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25749765','lexi-content-ref-14763949','lexi-content-ref-25930196']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25749765','lexi-content-ref-14763949','lexi-content-ref-25930196'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Neurotoxicity</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Cefepime-induced <b>neurotoxicity </b>(CIN) may occur and has been reported with use in adult and pediatric patients, including <b>altered mental status</b>, <b>aphasia</b>, <b>encephalopathy</b>, <b>impaired consciousness</b>, <b>myoclonus</b>, <b>seizure</b>, and nonconvulsive <b>status epilepticus</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31175111','lexi-content-ref-29260037','lexi-content-ref-30412900','lexi-content-ref-11498064','lexi-content-ref-29905577','lexi-content-ref-31201049']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31175111','lexi-content-ref-29260037','lexi-content-ref-30412900','lexi-content-ref-11498064','lexi-content-ref-29905577','lexi-content-ref-31201049'])">Ref</a></span>). Resolution of symptoms has been reported a median of 2 to 3 days after intervention (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35971666','lexi-content-ref-29137682']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35971666','lexi-content-ref-29137682'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Not clearly established; may be associated with concentration-dependent inhibition of GABA<sub>A</sub>-mediated neurotransmission (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32147665','lexi-content-ref-29137682']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32147665','lexi-content-ref-29137682'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Rapid; a median of 2 to 4 days after initiation has been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24200036','lexi-content-ref-35971666','lexi-content-ref-29137682']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24200036','lexi-content-ref-35971666','lexi-content-ref-29137682'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Excessive dosing; however, may also occur at appropriately adjusted doses (eg, for kidney impairment) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-37503476','lexi-content-ref-35615483','lexi-content-ref-35968536','lexi-content-ref-33614301','lexi-content-ref-29137682']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-37503476','lexi-content-ref-35615483','lexi-content-ref-35968536','lexi-content-ref-33614301','lexi-content-ref-29137682'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Elevated C<sub>min</sub> (trough) concentrations; risk also increases with increasing C<sub>min </sub>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36081354','lexi-content-ref-29137682']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36081354','lexi-content-ref-29137682'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Kidney impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-37503476','lexi-content-ref-36081354','lexi-content-ref-29137682']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-37503476','lexi-content-ref-36081354','lexi-content-ref-29137682'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Older age (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-37503476']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-37503476'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Preexisting brain injury (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36081354','lexi-content-ref-29137682']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36081354','lexi-content-ref-29137682'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F147285"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%: Hematologic &amp; oncologic: Positive direct Coombs test (without hemolysis: 16%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pruritus (≤1%), skin rash (1% to 4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hypophosphatemia (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Diarrhea (≤3%), nausea (≤2%), vomiting (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Abnormal partial thromboplastin time (2%), change in prothrombin time (1%), eosinophilia (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alanine aminotransferase (3%), increased serum aspartate aminotransferase (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction (in patients with a history of penicillin allergy: ≤10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Localized phlebitis (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Headache (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (≤1%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Erythema of skin, urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hypercalcemia, hyperkalemia, hyperphosphatemia, hypocalcemia</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: <i>Clostridioides difficile</i> colitis, oral candidiasis</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Vaginitis</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alkaline phosphatase, increased serum bilirubin</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Local inflammation, local pain</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Increased blood urea nitrogen, increased serum creatinine</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Acute generalized erythematous pustulosis (Botelho 2010), Stevens-Johnson syndrome (Marco-del Rio 2017)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: <i>Clostridioides difficile</i>-associated diarrhea (Thabit 2019)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Agranulocytosis (Medrano-Casique 2015), leukopenia (Jauregui 1993), neutropenia (Malincarne 2010), thrombocytopenia (Lim 2011)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Cholestatic hepatitis (Malhotra 2023, Yang 2022)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis (Moreno 2007), angioedema (Orhan 2004), drug reaction with eosinophilia and systemic symptoms (Qadri 2017)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Neurotoxicity (including abnormal gait [Shah 2021], agitation [Hambrick 2022], altered mental status [Payne 2017], aphasia [Isitan 2017], coma [Sonck 2008], confusion [Triplett 2019], encephalopathy [Triplett 2019], fine motor control disorder [Shah 2021], hallucination [Lamoth 2010], impaired consciousness [Payne 2017], myoclonus [Lizarraga 2019], seizure [Triplett 2019], slurred speech [Khorasani-Zadeh 2020], status epilepticus [nonconvulsive] [Garin 2019], stupor [Kim 2013], tremor [Hambrick 2022])</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Acute interstitial nephritis (Qadri 2017)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Eosinophilic pneumonitis (Jones 2021)</p></div>
<div class="block coi drugH1Div" id="F147301"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to cefepime, other cephalosporins, penicillins, other beta-lactam antibiotics, or any component of the formulation</p></div>
<div class="block war drugH1Div" id="F147282"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Elevated INR: May be associated with increased INR, especially in nutritionally deficient patients, prolonged treatment, hepatic or renal disease.</p>
<p style="text-indent:-2em;margin-left:4em;">• Superinfection: Prolonged use may result in fungal or bacterial superinfection.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Seizure disorders: Use with caution in patients with a history of seizure disorder.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Serious adverse reactions have occurred in elderly patients with renal insufficiency given unadjusted doses of cefepime, including life-threatening or fatal occurrences of encephalopathy, myoclonus, and seizures.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878373"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">The manufacturer does not recommend the use of cefepime in pediatric patients for the treatment of serious infections due to <i>Haemophilus influenzae</i> type b, for suspected meningitis, or for meningeal seeding from a distant infection site. However, cefepime has been shown to achieve adequate concentrations in the cerebrospinal fluid and has been evaluated in the treatment of CNS infections (including those caused by <i>H. influenzae </i>type b) (Ellis 2007; Sáez-Llorens 1995; Sáez-Llorens 2001; Sullins 2013). It is currently recommended for empiric treatment of health care-associated ventriculitis or meningitis, in combination with vancomycin, or for the directed treatment of susceptible bacterial meningitis (including that caused by <i>Pseudomonas aeruginosa)</i> (IDSA [Tunkel 2004]; IDSA [Tunkel 2017]).</p></div>
<div class="block foc drugH1Div" id="F147294"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 2 g/100 mL (100 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous, as hydrochloride [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1 g/50 mL (50 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Injection, as hydrochloride [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Maxipime: 2 g (1 ea [DSC])</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1 g (1 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous, as hydrochloride [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 2 g (1 ea); 100 g (1 ea); 1-5 GM-%(50ML) (1 ea); 2-5 GM-%(50ML) (1 ea)</p></div>
<div class="block geq drugH1Div" id="F147278"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F16323046"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Cefepime HCl Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 gm/50 mL (per mL): $0.65</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2 g/100 mL (per mL): $0.51</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Cefepime HCl Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 g (per each): $3.10 - $20.33</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Cefepime HCl Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2 g (per each): $5.76 - $40.36</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 g (per each): $570.00</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Cefepime-Dextrose Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1GM 5%(50ML) (per each): $23.62</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2GM 5%(50ML) (per each): $35.82</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52866234"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Injection, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1 g (1 ea); 2 g (1 ea)</p></div>
<div class="block admp drugH1Div" id="F52612379"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Parenteral:</p>
<p style="text-indent:-2em;margin-left:2em;">Intermittent IV infusion: Administer as an intermittent IV infusion over 30 minutes.</p>
<p style="text-indent:-2em;margin-left:2em;">Extended IV infusion: Administer over 3 to 4 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Beauchamp.1','lexi-content-ref-19422028','lexi-content-ref-25614528','lexi-content-ref-26810655']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Beauchamp.1','lexi-content-ref-19422028','lexi-content-ref-25614528','lexi-content-ref-26810655'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">IV push: In adults, limited data with IV push administration over 2 to 5 minutes at concentrations of 40 to 200 mg/mL have demonstrated this method to be generally safe and tolerable, but clinical outcomes have not been assessed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10630824','lexi-content-ref-34278415','lexi-content-ref-29095181','lexi-content-ref-30147136','lexi-content-ref-29046121']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10630824','lexi-content-ref-34278415','lexi-content-ref-29095181','lexi-content-ref-30147136','lexi-content-ref-29046121'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">IM: Administer by deep IM injection into large muscle mass.</p></div>
<div class="block adm drugH1Div" id="F147298"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>IM:</b> Inject deep IM into large muscle mass.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b> Administer as an intermittent infusion over 30 minutes. For extended-infusion administration (off-label method), administer over 3 to 4 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23571547','lexi-content-ref-19427167']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23571547','lexi-content-ref-19427167'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">IV push: Limited data with IV push administration over 2 to 5 minutes at concentrations of 40 to 200 mg/mL have demonstrated this method to be generally safe and tolerable, but outcomes have not been assessed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10630824','lexi-content-ref-34278415','lexi-content-ref-29095181','lexi-content-ref-30147136','lexi-content-ref-29046121']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10630824','lexi-content-ref-34278415','lexi-content-ref-29095181','lexi-content-ref-30147136','lexi-content-ref-29046121'])">Ref</a></span>).</p></div>
<div class="block sts drugH1Div" id="F2533513"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">Vials: Store intact vials at 20°C to 25°C (68°F to 77°F). Protect from light. After reconstitution, stable in NS and D5W for 24 hours at 20°C to 25°C (68°F to 77°F) and 7 days at 2°C to 8°C (36°F to 46°F). Refer to the manufacturer's product labeling for other acceptable reconstitution solutions.</p>
<p style="text-indent:-2em;margin-left:2em;">Dual chamber containers: Store unactivated containers at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 85°F). Do not freeze. Following reconstitution, use within 12 hours if stored at room temperature or within 5 days if stored under refrigeration.</p>
<p style="text-indent:-2em;margin-left:2em;">Premixed solution: Store frozen at -20°C (-4°F). Thawed solution is stable for 24 hours at room temperature or 7 days under refrigeration; do not refreeze.</p></div>
<div class="block usep drugH1Div" id="F53565915"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of pneumonia, uncomplicated skin and soft tissue infections, and complicated and uncomplicated urinary tract infections (including pyelonephritis) caused by susceptible organisms; empiric therapy for febrile neutropenic patients (FDA approved in ages ≥2 months and adults); treatment of complicated intra-abdominal infections in combination with metronidazole (FDA approved in adults); has also been used for meningitis, endocarditis, and the treatment of peritonitis in patients with peritoneal catheters.</p></div>
<div class="block mst drugH1Div" id="F9645319"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Cefepime may be confused with cefixime, cefTAZidime</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13298988"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F147287"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Aminoglycosides: Cephalosporins may enhance the nephrotoxic effect of Aminoglycosides. Cephalosporins may decrease the serum concentration of Aminoglycosides. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bacillus clausii: Antibiotics may diminish the therapeutic effect of Bacillus clausii.  Management: Bacillus clausii should be taken in between antibiotic doses during concomitant therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine.  Management: Avoid cholera vaccine in patients receiving systemic antibiotics, and within 14 days following the use of oral or parenteral antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Oral): May diminish the therapeutic effect of Antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Rectal): Antibiotics may diminish the therapeutic effect of Fecal Microbiota (Live) (Rectal). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Furosemide: May enhance the nephrotoxic effect of Cephalosporins.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies): Antibiotics may diminish the therapeutic effect of Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Probenecid: May increase the serum concentration of Cephalosporins.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Avoid use of live attenuated typhoid vaccine (Ty21a)  in patients being treated with systemic antibacterial agents. Postpone vaccination until 3 days after cessation of antibiotics and avoid starting antibiotics within 3 days of last vaccine dose.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): Cephalosporins may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F5947925"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Cefepime crosses the placenta (Ozyuncu 2010).</p>
<p style="text-indent:0em;margin-top:2em;">An increased risk of major birth defects or other adverse fetal or maternal outcomes has generally not been observed following use of cephalosporin antibiotics during pregnancy.</p>
<p style="text-indent:0em;margin-top:2em;">When an antibiotic is needed for the treatment of maternal infection, cefepime can be considered. However, other, more well-studied cephalosporins are preferred for use in pregnancy (Betschart 2020; ERS/TSANZ [Middleton 2020]; Panchaud 2016).</p></div>
<div class="block mopp drugH1Div" id="F53565917"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">With prolonged therapy, monitor renal and hepatic function periodically; number and type of stools/day for diarrhea; serum phosphorus (Knoderer 2018); CBC with differential. Monitor closely for signs and symptoms of hypersensitivity including anaphylaxis.</p></div>
<div class="block rerp drugH1Div" id="F57571467"><span class="drugH1">Reference Range</span>
<p style="text-indent:-2em;margin-left:2em;">Cefepime concentration monitoring is not routine, but may be considered in certain scenarios (eg, critically ill patients, patients with organ failure or the expectation of altered pharmacokinetics [ie, extracorporeal membrane oxygenation, continuous renal replacement therapy, augmented renal clearance], or pathogens with minimum inhibitory concentrations (MICs) at, near, or above the susceptibility breakpoint) (Cies 2018; Fratoni 2021; Roberts 2018; Stitt 2019; Zuppa 2019).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Monitoring approaches are not standardized; various approaches and suggested targets exist. Refer to institutional protocols if available (Fratoni 2021; Morales 2022).</p>
<p style="text-indent:-2em;margin-left:2em;">Target:</p>
<p style="text-indent:-2em;margin-left:4em;">Efficacy: Non-protein bound (free) serum concentration should exceed the pathogen MIC for ~60% to 100% of the dosing interval (ie, <i>f</i>T&gt;MIC of ≥60% to 100%) (Fratoni 2021; Roberts 2014; Shoji 2016; Stitt 2019; Zuppa 2019). Some authors have suggested more aggressive targets, such as concentration exceeding 4 times the pathogen MIC for 40% to 100% of the dosing interval, but it's unclear whether these targets are necessary (Cies 2018; Fratoni 2021; Roberts 2018; Stitt 2019).</p>
<p style="text-indent:-2em;margin-left:4em;">Toxicity: Neurotoxicity risk increases with increasing concentration. In adults, trough concentrations &gt;16 to 22 mg/L for intermittent dosing or steady state concentrations &gt;35 mg/L for continuous infusion dosing have been associated with increased risk of neurotoxicity; pediatric-specific data are not available (Boschung-Pasquier 2020; Fratoni 2021; Guilhaumou 2019; Huwyler 2017).</p>
<p style="text-indent:-2em;margin-left:2em;">Timing of serum sampling: Several methods have been described:</p>
<p style="text-indent:-2em;margin-left:4em;">Single sample: A single concentration obtained midway through the dosing interval (eg, 50%) or at the end of the dosing interval (trough; just before the next dose) can be compared to desired threshold (Fratoni 2021).</p>
<p style="text-indent:-2em;margin-left:4em;">Multiple sample: ≥2 to 3 concentrations may be obtained during the dosing interval (eg, peak and trough, multiple mid-interval concentrations). Values may then be utilized with population PK and Bayesian modeling software, or for calculation of patient-specific pharmacokinetic parameters and time above MIC using standard pharmacokinetic equations (Cies 2018; Fratoni 2021).</p></div>
<div class="block pha drugH1Div" id="F147281"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Inhibits bacterial cell wall synthesis by binding to one or more of the penicillin-binding proteins (PBPs) which in turn inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls, thus inhibiting cell wall biosynthesis. Bacteria eventually lyse due to ongoing activity of cell wall autolytic enzymes (autolysis and murein hydrolases) while cell wall assembly is arrested.</p></div>
<div class="block phk drugH1Div" id="F147300"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: IM: Rapid and complete.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution:</p>
<p style="text-indent:-2em;margin-left:4em;">V<sub>d</sub>:</p>
<p style="text-indent:-2em;margin-left:6em;">Neonates (Capparelli 2005):</p>
<p style="text-indent:-2em;margin-left:8em;">PMA &lt;30 weeks: 0.51 L/kg.</p>
<p style="text-indent:-2em;margin-left:8em;">PMA &gt;30 weeks: 0.39 L/kg.</p>
<p style="text-indent:-2em;margin-left:6em;">Infants ≥2 months and children ≤11 years: 0.3 ± 0.1 L/kg.</p>
<p style="text-indent:-2em;margin-left:6em;">Adults: 18 L, 0.26 L/kg; penetrates into inflammatory fluid at concentrations ~80% of serum concentrations and into bronchial mucosa at concentrations ~60% of plasma concentrations; crosses the blood-brain barrier.</p>
<p style="text-indent:-2em;margin-left:4em;">Cerebrospinal fluid (CSF):</p>
<p style="text-indent:-2em;margin-left:6em;">Neonates (Ellis 2007):</p>
<p style="text-indent:-2em;margin-left:8em;">Preterm (n=2): CSF:serum ratio (C<sub>min</sub>): ~30% to 87.6%.</p>
<p style="text-indent:-2em;margin-left:8em;">Term (n=7): CSF:serum ratio (C<sub>min</sub>): ~3.1% to 59.7%.</p>
<p style="text-indent:-2em;margin-left:6em;">Infants ≥2 months, Children, and Adolescents ≤15 years: CSF:serum ratio: 9% at 30 minutes after dose, increasing to 67% at 8 hours after dose (Sáez-Llorens 1995).</p>
<p style="text-indent:-2em;margin-left:6em;">Adults: CSF:serum ratio: 4% to 34% (AUC); 5% to 58% (C<sub>min</sub>) (Rhoney 2003).</p>
<p style="text-indent:-2em;margin-left:4em;">Lung:</p>
<p style="text-indent:-2em;margin-left:6em;">Epithelial lining fluid:serum ratio: ~100% (Boselli 2003; Breilh 2001).</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding, plasma: ~20%.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Minimally hepatic.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination:</p>
<p style="text-indent:-2em;margin-left:4em;">Neonates: 4 to 5 hours (Lima-Rogel 2008).</p>
<p style="text-indent:-2em;margin-left:4em;">Children 2 months to 6 years of age: 1.77 to 1.96 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: 2 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Hemodialysis: 13.5 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Continuous peritoneal dialysis: 19 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: IM: 1 to 2 hours; IV: 0.5 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (85% as unchanged drug).</p></div>
<div class="block phksp drugH1Div" id="F51192714"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: Total body clearance is decreased proportionally with creatinine clearance.</p>
<p style="text-indent:-2em;margin-left:2em;">Anti-infective considerations:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Parameters associated with efficacy:</i> Time dependent; associated with time free drug concentration (<i>f</i>T) &gt; minimum inhibitory concentration (MIC).</p>
<p style="text-indent:-2em;margin-left:6em;">Organism specific:</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Staphylococcus spp.</i>: Goal: 40% <i>f</i>T &gt; MIC (bactericidal in vitro) (Craig 1995).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Streptococcus spp.</i>: Goal: 40% <i>f</i>T &gt; MIC (bacteriostatic in vitro), 60% to 70% <i>f</i>T &gt; MIC (bactericidal in vitro) (Craig 1995).</p>
<p style="text-indent:-2em;margin-left:8em;">Gram negative bacteria (including <i>P. aeruginosa</i>): Goal: 40% <i>f</i>T &gt; MIC (bacteriostatic in vitro); 60% to 70% <i>f</i>T &gt; MIC (bactericidal in vitro); 53% to 60% <i>f</i>T &gt; MIC (microbiological response) (Craig 1995; Craig 1998; Crandon 2010; MacVane 2014a; Roos 2006).</p>
<p style="text-indent:-2em;margin-left:6em;">Population specific:</p>
<p style="text-indent:-2em;margin-left:8em;">Critically ill patients in the ICU: Minimum goal: ≥50%<i> f</i>T &gt; MIC; preferred goal: ≥100% <i>f</i>T &gt; MIC (Roberts 2014); some experts favor ≥100%<i> f</i>T &gt;4 times the MIC (Guilhaumou 2019).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Postantibiotic effect:</i> Generally little to no postantibiotic effect for <i>Streptococcus spp.</i> and gram negative bacilli (including <i>P.</i>
<i>aeruginosa</i>); prolonged postantibiotic effect for <i>Staphylococcus spp</i>. (Craig 1991; Craig 1995; Craig 1998; Ozbek 2009).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Parameters associated with toxicity:</i> Neurotoxicity (eg, confusion, altered consciousness, seizures) is associated with elevated C<sub>min</sub> (trough) concentrations and risk increases with increasing C<sub>min</sub>; however, a specific C<sub>min</sub> associated with neurotoxicity has not been well established (Boschung-Pasquier 2020; Huwyler 2017; Lamoth 2010; Payne 2017). In 2 small studies, C<sub>min</sub> of ≥22 mg/L and &gt;35 mg/L were associated with neurotoxicity (Huwyler 2017; Lamoth 2010). In a study assessing cefepime therapeutic drug monitoring in adults, C<sub>min</sub> &lt;7.7 mg/L resulted in no neurotoxicity, C<sub>min</sub> ≥12 mg/L was associated with a 25% probability of neurotoxicity, C<sub>min</sub> ≥16 mg/L was associated with a 50% probability of neurotoxicity, and C<sub>min</sub> ≥38.1 mg/L was always associated with neurotoxicity (Boschung-Pasquier 2020).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Expected drug concentrations in patients with normal renal function:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Neonates (Shoji 2016): C<sub>max </sub>(peak): IV:</p>
<p style="text-indent:-2em;margin-left:8em;">GA &lt;36 weeks: ~50 mg/kg/dose every 12 hours, steady state: 190.02 ± 31.25 mg/L.</p>
<p style="text-indent:-2em;margin-left:8em;">GA ≥36 weeks: ~50 mg/kg/dose every 12 hours, steady state: 192.92 ± 19.64 mg/L.</p>
<p style="text-indent:-2em;margin-left:6em;">Infants and children 2 months to 16 years of age; hospitalized: C<sub>max</sub> (peak): IV:</p>
<p style="text-indent:-2em;margin-left:8em;">50 mg/kg/dose every 8 hours, steady state: 184.2 ± 38 mg/L (Reed 1997).</p>
<p style="text-indent:-2em;margin-left:6em;">Adults: C<sub>max</sub> (peak): IV:</p>
<p style="text-indent:-2em;margin-left:8em;">30-minute infusion, healthy volunteers:</p>
<p style="text-indent:-2em;margin-left:10em;">1 g, single dose: 81.7 ± 5.1 mg/L.</p>
<p style="text-indent:-2em;margin-left:10em;">1 g every 8 hours, steady state (day 6): 70.5 ± 8.5 mg/L (Barbhaiya 1992).</p>
<p style="text-indent:-2em;margin-left:10em;">2 g, single dose: 163.9 ± 25.3 mg/L.</p>
<p style="text-indent:-2em;margin-left:10em;">2 g every 8 hours, steady state (day 6): 129 ± 27.1 mg/L (Barbhaiya 1992).</p>
<p style="text-indent:-2em;margin-left:8em;">4-hour infusion, hospitalized patients requiring antibiotics:</p>
<p style="text-indent:-2em;margin-left:10em;">1 g every 8 hours, steady state: 32.5 ± 13.5 mg/L (Cheatham 2011).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F147304"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Maxipime | Pozineg | Protec | Qpime</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Cefepime northia | Cefepime pharmavia | Cefepime richet | Cefimen K | Fada cefepime | Maxcef | Rivepime</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Cefepim Amomed | Cefepim mip | Cefepim Sandoz | Cefepime accord | Maxipime</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Cefepime aft | Cefepime alphapharm | Cefepime Kabi | DBL Cefepime | Maxipime | Omegapharm Cefepime</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Axepime | Cefa 4 | Ceftipime | Efepime | Forgen | Japime | Magnova | Maxpime | Megapime | Superpime | Tetracef | Ultrapime | Winnipime | Xenim | Ximepime | Zopime</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Cefepim Fresenius Kabi | Cefepim mip | Cefepim Sandoz | Cefepime ldp laboratorios torlan | Cefepime noridem | Maxipime</span>;</li>
<li>
<span class="countryCode">(BF)</span> <span class="country">Burkina Faso</span><span class="countrySeparator">: </span><span class="drugName">Kefpime | Pozineg | Zipime</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Alphacef | Bacteripime | Cefepim | Cefepime Kabi | Cefepime panpharma | Critipime | Maxipime</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Cefepima Cloridrato | Cemax | Cloridrato de cefepima | Cloridrato de cefepime | Maxcef | Nepecef</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Cefepim Sandoz | Cefepime Orpha | Maxipime</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Kefpime | Micropime | Pozineg | Sanpime | Ultrapime | Zipime</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Cefepima | Maxipime</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Cefepime dihydrochloride | Da li neng | Heng su | Ka luo xin | Kang li wo pu | Lai bi xin | Li si ping | Maxipime | Maxipimg | Pai nai xin | Xin li wei</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Cefdeltime | Cefemin | Cefepima | Cefepime | Imation | Maxipime | Pimecef | Pozineg | Salapime</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Cefepim noridem | Cefepime accord | Maxipime</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Cefepim mip | Cefepim panpharma | Cefepim qilu | Cefepim stragen | Cefepime rotexmedica | Maxipime</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Cefepima | Cefepime | Cefepime sintesis | Cefime | Cipime | Efectus | Kabol | Maxipime | Pramur</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Cefepima | Cefepime | Cefepime richet | Cefimen-k | Maxipime</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Alphacef | Cefepime | Cefepime norameda | Maxipime | Renapime</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Cefepime | Cepimax | Curafep | Forcetex | Kempopim | Maxipime | Pimfast | Vanzapro | Wincef | Zovijectin</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Cefepima | Cefepima combino | Cefepima hospira | Cefepima kabi | Cefepima normon | Cefepima qilu | Cefepima sala | Maxipime</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Cefepime HCL | Injpime | Necpime | Pozineg | Protec | Sanpime</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Cefepim MIP Pharma | Cefepime norameda | Maxipime</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Axepim | Cefepime accord | Cefepime Dci | Cefepime gerda | Cefepime Mylan | Cefepime noridem | Cefepime panpharma | Cefepime stragen</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Renapime</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Cefepime/alvia | Cefepime/kabi | Gencef | Maxinject | Maxipime | Verapime | Zefipime</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Maxipime</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Cefepime Kabi | Maxipime</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Cefepime mip | Maxipime</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Actacef | Biocepime | Caprifim | Cefepime | Cefinov | Daryacef | Emax | Exepime | Falocef | Futapim | Interpim | Macef | Maxicef | Maxilan | Maximer | Maxipime | Procepim | Sandocef | Sopime | Vipime</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Maxcef</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Adpime | Biopime | Blucef XL | C pime | Cachepime | Cefdiel-i | Cefeprime | Ceficad | Cefpy | Celrim | Cepime | Cepy | Epime | Forpar | Ivipime | Kefage | Kefpime | Kepime | Kingcef | Mapime | Maxicef | Maxopime | Megapime | Micropime | Nitipime | Novapime | Orpime | Pozineg | Pryme | Radipime | Refpim | Safepime | Scud | Sefdin | Ultipime | Vegapime | Winpime | Zipime | Zwiter</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Cepim | Cepimex | Maxipime</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Cepim | Maxipime</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Cefepime HCL | Cefepime hydrochloride Cmx | Maxipime bristol myers | Maxipime meiji</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">C pime | Cefepimark | Ceficad | Ceftipime | Forpar | Injpime | Inno pime | Kopime | Maxime | Megapime | Micropime | Necpime | Pimcef | Pimefast | Pozineg | Skypime | Teico | Totacef | Ultrapime</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Acepime | Alvogen cefepime hcl | Cefem | Maxipime boryung | Newcepim | Newsepim</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Deltacef | Maxipime | Protec</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Cefepime panpharma | Cefipex | Maxipime | Qpime</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Cefepime mip | Cefepime norameda | Maxipime</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Maxipime</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Cefepime mip | Cefepime norameda | Maxipime</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Protec</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Cefepima | Feriticefin | Imation | Makenpime | Maxef | Maxipime | Pimerzen | Pozineg | Suloval | Toblefam | Vipefime</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Cefepen | Ceficad | Cefmex | Forpar | Maxipime | Sefepim | Verapime</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Asceftra</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Cefepim</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Cefepime | Cefepime aft | Cefepime Kabi | DBL Cefepime | Maxipime</span>;</li>
<li>
<span class="countryCode">(OM)</span> <span class="country">Oman</span><span class="countrySeparator">: </span><span class="drugName">Protec</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Cefepima | Cefepimek | Maxipime | Megapime | Norcef | Pimcef</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">4 gen 1000 | Alcemax | Altamax | Axera | Cefepime | Cefevex | Cefime | Cepimax | Cepiram | Dimipra | Extemax | Kevon | Medipime | Megapime | Neupime | Pimevex | Pozineg | Sanpime | Sefepim | Sefpime | Sepime | Spectrax | Stafipime | Supime | Vipefime | Zepim</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Adpime | Afipime | Aleeva | Alipime | Axepime | Axipime | Baxipime | Cef hy | Cefevial | Cefgram | Cefi | Cefigen | Cefipar | Cefipime | Cefstar | Cerapime | Daypime | Dizma 4 | Elide | Emipref | Emty | Endopime | Feldopim | Fredipime | Gepin | Gu pime | Jewpime | Kanpime | Magnapime | Markpime | Maxipime | Maxpin | Maxum | Medipime | Megapime | Mepime | Neupime | New pime | Novapime | Nuxipim | Olipime | On cef | Palfepim | Pefmad | Perin | Pimalin | Pimazon | Pime | Pimecef | Pimeranis | Pimerive | Pimestar | Pimporin | Puna | Siodime | Solopime | Swisspime | Uceph | Unipime | Uspime | Vegapime | Verapime | Voco | Winpime | Zepim</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Cefepim MIP Pharma | Cefepime Kabi | Cefepime panpharma | Critipeme | Maxipime</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Cefepime | Cefepime HCL | Maxipime</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Cefepima accord | Cefepima basi | Cefepima hospira | Cefepima kabi | Cefepima normon | Maxipime</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Acedrin | Cefepima libra | Cefepima medicine | Cefepima vmg | Cefepime prosalud | Cefepime richet | Cefinina | Clorhidrato de cefepima | Fada cefepime</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Cepim | Deltacef | Pozineg | Protec</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Cefepime Kabi</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Cefepim | Cefepime | Cefepime agio | Cefepime alkem | Cefepime jodas | Cefepime vial | Cefomax | Cepim | Cling | Decefim | Efipime | Kefsepim | Ladef | Maxicef | Maxipime | Maxycef | Movizar</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Cefepime | Deltacef | Maxipime | Vanzapro</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Cefepim mip | Maxipime</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Maxipime</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Cefepim kabi | Maxipime</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Cefepim noridem | Maxipime</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Aspime | Cefamax | Maxipime | Megapime | Orpime | Pime | Sefpime</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Avipim | Ekipim | Maxipime | Roxipime | Unisef</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Antifect | Cefemax | Cefepime | Cefepin | Cefim | Funjapin | Macepim | Maxipime | Supecef | Tisan | Yupime</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Abypim | Blipime | Brodipime | Cebopime | Cefepim | Cefepime | Cefepime vista | Cefepimum | Ceficad | Cefimek | Cefotrine | Cepim | Espim | Exipime | Extencef | Fortacef | Kefpime | Maxinort | Maxipim | Megapim | Novapim | Pikcef | Pozineg | Quadrocef | Quartacef | Roxipim | Sanpime | Septipim | Ukpime 1000</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Ceficad | Megapime | Necpime | Pimcef | Pozineg | Sanpime | Teico | Vaxcel cefepime | Welzpime</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Cefepime northia | Cepim | Maxcef</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Cefepima | Forpar | Maxipime | Necpime | Pimcef | Sanpime</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Bapexim | Cefeme | Cefpas | Dixapim</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Auro cefepime | Cefepime actor | Cefepime safeline | Critipeme | Maxipime</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Forcepime | Micropime | Necpime | Novapime | Orpime</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-26754759">
<a name="26754759"></a>Abdul-Aziz MH, Sulaiman H, Mat-Nor MB, et al. Beta-Lactam Infusion in Severe Sepsis (BLISS): a prospective, two-centre, open-labelled randomised controlled trial of continuous versus intermittent beta-lactam infusion in critically ill patients with severe sepsis. <i>Intensive Care Med</i>. 2016;42(10):1535-1545. doi:10.1007/s00134-015-4188-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/26754759/pubmed" id="26754759" target="_blank">26754759</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37503476">
<a name="37503476"></a>Ajibola O, Aremu TO, Dada SO, et al. The trend of cefepime-induced neurotoxicity: a systematic review. <i>Cureus</i>. 2023;15(6):e40980. doi:10.7759/cureus.40980<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/37503476/pubmed" id="37503476" target="_blank">37503476</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11036058">
<a name="11036058"></a>Alkharfy KM, Kellum JA, Frye RF, Matzke GR. Effect of ceftazidime on systemic cytokine concentrations in rats. <i>Antimicrob Agents Chemother</i>. 2000;44(11):3217-3219. doi:10.1128/aac.44.11.3217-3219.2000<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/11036058/pubmed" id="11036058" target="_blank">11036058</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9371344">
<a name="9371344"></a>Allaouchiche B, Breilh D, Jaumain H, Gaillard B, Renard S, Saux MC. Pharmacokinetics of cefepime during continuous venovenous hemodiafiltration. <i>Antimicrob Agents Chemother</i>. 1997;41(11):2424-2427. doi:10.1128/AAC.41.11.2424<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/9371344/pubmed" id="9371344" target="_blank">9371344</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24474430">
<a name="24474430"></a>Alves MD, Ribeiro VB, Tessari JP, et al. Effect of cefepime dose on mortality of patients with gram-negative bacterial bloodstream infections: a prospective cohort study. <i>J Antimicrob Chemother.</i> 2014;69(6):1681-1687. doi:10.1093/jac/dku001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/24474430/pubmed" id="24474430" target="_blank">24474430</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AAP.1">
<a name="AAP.1"></a>American Academy of Pediatrics (AAP). In: Kimberlin DW, Brady MT, Jackson MA, Long SA, eds. <i>Red Book: 2018 Report of the Committee on Infectious Diseases</i>. 31st ed. American Academy of Pediatrics; 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AAP.2">
<a name="AAP.2"></a>American Academy of Pediatrics (AAP). In: Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH, eds. <i>Red Book: 2021 Report of the Committee on Infectious Diseases</i>. 32nd ed. American Academy of Pediatrics; 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1496945">
<a name="1496945"></a>Arguedas AG, Stutman HR, Zaleska M, et al. Cefepime. Pharmacokinetics and Clinical Response in Patients With Cystic Fibrosis. <i>Am J Dis Child</i>. 1992;146(7):797-802. doi:10.1001/archpedi.1992.02160190029013<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/1496945/pubmed" id="1496945" target="_blank">1496945</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23341160">
<a name="23341160"></a>Arnold HM, Hollands JM, Skrupky LP, et al. Prolonged infusion antibiotics for suspected gram-negative infections in the ICU: a before-after study.<i> Ann Pharmacother.</i> 2013;47(2):170-180. doi:10.1345/aph.1R523<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/23341160/pubmed" id="23341160" target="_blank">23341160</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Aronoff.1">
<a name="Aronoff.1"></a>Aronoff GR, Bennett WM, Berns JS, et al. <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children.</i> 5th ed. American College of Physicians; 2007.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26373317">
<a name="26373317"></a>Baltimore RS, Gewitz M, Baddour LM, et al; American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young and the Council on Cardiovascular and Stroke Nursing. Infective endocarditis in childhood: 2015 update: a scientific statement from the American Heart Association. <i>Circulation</i>. 2015;132(15):1487-1515. doi:10.1161/CIR.0000000000000298<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/26373317/pubmed" id="26373317" target="_blank">26373317</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1622165">
<a name="1622165"></a>Barbhaiya RH, Forgue ST, Gleason CR, et al. Pharmacokinetics of cefepime after single and multiple intravenous administrations in healthy subjects. <i>Antimicrob Agents Chemother.</i> 1992;36(3):552-557. doi:10.1128/aac.36.3.552<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/1622165/pubmed" id="1622165" target="_blank">1622165</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27080992">
<a name="27080992"></a>Barlam TF, Cosgrove SE, Abbo LM, et al. Implementing an antibiotic stewardship program: guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America. <i>Clin Infect Dis</i>. 2016;62(10):e51-e77. doi:10.1093/cid/ciw118<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/27080992/pubmed" id="27080992" target="_blank">27080992</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Barshak.1">
<a name="Barshak.1"></a>Barshak MB. Antimicrobial approach to intra-abdominal infections in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 6, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23571547">
<a name="23571547"></a>Bauer KA, West JE, O'Brien JM, Goff DA. Extended-infusion cefepime reduces mortality in patients with <i>Pseudomonas aeruginosa</i> infections. <i>Antimicrob Agents Chemother</i>. 2013;57(7):2907-1292. doi:10.1128/AAC.02365-12<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/23571547/pubmed" id="23571547" target="_blank">23571547</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Beauchamp.1">
<a name="Beauchamp.1"></a>Beauchamp LC, Nichols KR, Knoderer CA. Outcomes of extended infusion cefepime in pediatric patients. <i>Infect Dis Clin Pract.</i> 2019;27(5):283-287.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35615483">
<a name="35615483"></a>Behal ML, Thomas JK, Thompson Bastin ML, Mefford BM. Cefepime induced neurotoxicity following a regimen dose-adjusted for renal function: case report and review of the literature. <i>Hosp Pharm</i>. 2022;57(3):385-391. doi:10.1177/00185787211046856<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/35615483/pubmed" id="35615483" target="_blank">35615483</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Berbari.1">
<a name="Berbari.1"></a>Berbari E, Baddour LM, Chen AF. Prosthetic joint infection: Treatment. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 10, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26229122">
<a name="26229122"></a>Berbari EF, Kanj SS, Kowalski TJ, et al; Infectious Diseases Society of America. 2015 Infectious Diseases Society of America (IDSA) clinical practice guidelines for the diagnosis and treatment of native vertebral osteomyelitis in adults. <i>Clin Infect Dis</i>. 2015;61(6):e26-e46. doi:10.1093/cid/civ482<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/26229122/pubmed" id="26229122" target="_blank">26229122</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32365216">
<a name="32365216"></a>Betschart C, Albrich WC, Brandner S, et al. Guideline of the Swiss Society of Gynaecology and Obstetrics (SSGO) on acute and recurrent urinary tract infections in women, including pregnancy. <i>Swiss Med Wkly</i>. 2020;150:w20236. doi:10.4414/smw.2020.20236<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/32365216/pubmed" id="32365216" target="_blank">32365216</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24886826">
<a name="24886826"></a>Beumier M, Casu GS, Hites M, et al. β-lactam antibiotic concentrations during continuous renal replacement therapy. <i>Crit Care</i>. 2014;18(3):R105. doi:10.1186/cc13886<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/24886826/pubmed" id="24886826" target="_blank">24886826</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30558872">
<a name="30558872"></a>Blumenthal KG, Peter JG, Trubiano JA, Phillips EJ. Antibiotic allergy. <i>Lancet</i>. 2019;393(10167):183-198. doi:10.1016/S0140-6736(18)32218-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/30558872/pubmed" id="30558872" target="_blank">30558872</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29909695">
<a name="29909695"></a>Bodilsen J, Brouwer MC, Nielsen H, Van De Beek D. Anti-infective treatment of brain abscess. <i>Expert Rev Anti Infect Ther.</i> 2018;16(7):565-578. doi:10.1080/14787210.2018.1489722<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/29909695/pubmed" id="29909695" target="_blank">29909695</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28044125">
<a name="28044125"></a>Bond A, Manian FA. Spinal epidural abscess: a review with special emphasis on earlier diagnosis. <i>Biomed Res Int</i>. Published online December 1, 2016. doi:10.1155/2016/1614328<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/28044125/pubmed" id="28044125" target="_blank">28044125</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31284030">
<a name="31284030"></a>Boschung-Pasquier L, Atkinson A, Kastner LK, et al. Cefepime neurotoxicity: thresholds and risk factors. A retrospective cohort study. <i>Clin Microbiol Infect</i>. 2020;26(3):333-339. doi:10.1016/j.cmi.2019.06.028<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/31284030/pubmed" id="31284030" target="_blank">31284030</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12973166">
<a name="12973166"></a>Boselli E, Breilh D, Duflo F, et al. Steady-state plasma and intrapulmonary concentrations of cefepime administered in continuous infusion in critically ill patients with severe nosocomial pneumonia. <i>Crit Care Med</i>. 2003;31(8):2102-2106. doi:10.1097/01.CCM.0000069734.38738.C8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/12973166/pubmed" id="12973166" target="_blank">12973166</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21103192">
<a name="21103192"></a>Botelho LF, Picosse FR, Padilha MH, Michalany N, Góis A, Porro AM. Acute generalized exanthematous pustulosis induced by cefepime: a case report. <i>Case Rep Dermatol</i>. 2010;2(2):82-87. doi:10.1159/000314474<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/21103192/pubmed" id="21103192" target="_blank">21103192</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bradley.3">
<a name="Bradley.3"></a>Bradley JS, Nelson JD, Kimberlin DK, et al, eds. <i>Nelson's Pocket Book of Pediatric Antimicrobial Therapy</i>. 28th ed. American Academy of Pediatrics; 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11273786">
<a name="11273786"></a>Breilh D, Saux MC, Delaisement C, et al. Pharmacokinetic population study to describe cefepime lung concentrations. <i>Pulm Pharmacol Ther</i>. 2001;14(2):69-74. doi:10.1006/pupt.2000.0269<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/11273786/pubmed" id="11273786" target="_blank">11273786</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26120552">
<a name="26120552"></a>Brockow K, Przybilla B, Aberer W, et al. Guideline for the diagnosis of drug hypersensitivity reactions: S2K-Guideline of the German Society for Allergology and Clinical Immunology (DGAKI) and the German Dermatological Society (DDG) in collaboration with the Association of German Allergologists (AeDA), the German Society for Pediatric Allergology and Environmental Medicine (GPA), the German Contact Dermatitis Research Group (DKG), the Swiss Society for Allergy and Immunology (SGAI), the Austrian Society for Allergology and Immunology (ÖGAI), the German Academy of Allergology and Environmental Medicine (DAAU), the German Center for Documentation of Severe Skin Reactions and the German Federal Institute for Drugs and Medical Products (BfArM). <i>Allergo J Int</i>. 2015;24(3):94-105. doi:10.1007/s40629-015-0052-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/26120552/pubmed" id="26120552" target="_blank">26120552</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23478961">
<a name="23478961"></a>Brown KA, Khanafer N, Daneman N, Fisman DN. Meta-analysis of antibiotics and the risk of community-associated Clostridium difficile infection. <i>Antimicrob Agents Chemother</i>. 2013;57(5):2326-2332. doi:10.1128/AAC.02176-12<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/23478961/pubmed" id="23478961" target="_blank">23478961</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36324356">
<a name="36324356"></a>Budh DP, Hawa S, Rios D, Chilakala A, Paniagua JA. Acute generalized exanthematous pustulosis in a setting of cutaneous lymphoma. <i>Cureus</i>. 2022;14(9):e29754. doi:10.7759/cureus.29754<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/36324356/pubmed" id="36324356" target="_blank">36324356</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25575975">
<a name="25575975"></a>Burgess SV, Mabasa VH, Chow I, Ensom MH. Evaluating outcomes of alternative dosing strategies for cefepime: a qualitative systematic review. <i>Ann Pharmacother</i>. 2015;49(3):311-322. doi:10.1177/1060028014564179<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/25575975/pubmed" id="25575975" target="_blank">25575975</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15980347">
<a name="15980347"></a>Capparelli E, Hochwald C, Rasmussen M, et al. Population pharmacokinetics of cefepime in the neonate. <i>Antimicrob Agents Chemother.</i> 2005;49(7):2760-2766. doi:10.1128/AAC.49.7.2760-2766.2005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/15980347/pubmed" id="15980347" target="_blank">15980347</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26208469">
<a name="26208469"></a>Carlier M, Taccone FS, Beumier M, et al. Population pharmacokinetics and dosing simulations of cefepime in septic shock patients receiving continuous renal replacement therapy. <i>Int J Antimicrob Agents</i>. 2015;46(4):413-419. doi:10.1016/j.ijantimicag.2015.05.020<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/26208469/pubmed" id="26208469" target="_blank">26208469</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cefepime.1">
<a name="Cefepime.1"></a>Cefepime injection [prescribing information]. Chicago, IL: Meitheal Pharmaceuticals Inc; November 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cefepime.2">
<a name="Cefepime.2"></a>Cefepime injection [prescribing information]. Deerfield, IL: Baxter; May 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cefepime.4">
<a name="Cefepime.4"></a>Cefepime injection [prescribing information]. Buffalo Grove, IL: Xellia Pharmaceuticals; August 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cefepime.3">
<a name="Cefepime.3"></a>Cefepime hydrochloride and dextrose [prescribing information]. Bethlehem, PA: B. Braun Medical Inc; March 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CDC.2022">
<a name="CDC.2022"></a>Centers for Disease Control and Prevention (CDC). FAQs for clinicians about <i>C. diff. </i>
<a href="https://www.cdc.gov/cdiff/clinicians/faq.html" target="_blank">https://www.cdc.gov/cdiff/clinicians/faq.html</a>. Updated October 25, 2022. Accessed January 8, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30221005">
<a name="30221005"></a>Chaijamorn W, Charoensareerat T, Srisawat N, Pattharachayakul S, Boonpeng A. Cefepime dosing regimens in critically ill patients receiving continuous renal replacement therapy: a Monte Carlo simulation study.<i> J Intensive Care</i>. 2018;6:61. doi:10.1186/s40560-018-0330-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/30221005/pubmed" id="30221005" target="_blank">30221005</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21074370">
<a name="21074370"></a>Cheatham SC, Shea KM, Healy DP, et al. Steady-state pharmacokinetics and pharmacodynamics of cefepime administered by prolonged infusion in hospitalised patients.<i> Int J Antimicrob Agents.</i> 2011;37(1):46-50. doi:10.1016/j.ijantimicag.2010.08.016<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/21074370/pubmed" id="21074370" target="_blank">21074370</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29112080">
<a name="29112080"></a>Cies JJ, Moore WS 2nd, Enache A, Chopra A. β-lactam therapeutic drug management in the PICU. <i>Crit Care Med</i>. 2018;46(2):272-279. doi:10.1097/CCM.0000000000002817<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/29112080/pubmed" id="29112080" target="_blank">29112080</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24755188">
<a name="24755188"></a>Collins CE, Ayturk MD, Flahive JM, Emhoff TA, Anderson FA Jr, Santry HP. Epidemiology and outcomes of community-acquired Clostridium difficile infections in Medicare beneficiaries. <i>J Am Coll Surg</i>. 2014;218(6):1141-1147.e1. doi:10.1016/j.jamcollsurg.2014.01.053<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/24755188/pubmed" id="24755188" target="_blank">24755188</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19422028">
<a name="19422028"></a>Courter JD, Kuti JL, Girotto JE, Nicolau DP. Optimizing bactericidal exposure for beta-lactams using prolonged and continuous infusions in the pediatric population. <i>Pediatr Blood Cancer</i>. 2009;53(3):379‐385. doi:10.1002/pbc.22051<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/19422028/pubmed" id="19422028" target="_blank">19422028</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7587056">
<a name="7587056"></a>Craig WA. Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins. <i>Diagn Microbiol Infect Dis.</i> 1995;22(1-2):89-96. doi:10.1016/0732-8893(95)00053-d<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/7587056/pubmed" id="7587056" target="_blank">7587056</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9455502">
<a name="9455502"></a>Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. <i>Clin Infect Dis</i>. 1998;26(1):1-10. doi:10.1086/516284<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/9455502/pubmed" id="9455502" target="_blank">9455502</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Craig.1">
<a name="Craig.1"></a>Craig WA. The postantibiotic effect.<i> Clin Microbiol Newsletter</i>. 1991;13(16):121-124. doi:10.1016/0196-4399(91)90030-Y</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20038614">
<a name="20038614"></a>Crandon JL, Bulik CC, Kuti JL, Nicolau DP. Clinical pharmacodynamics of cefepime in patients infected with <i>Pseudomonas aeruginosa</i>. <i>Antimicrob Agents Chemother.</i> 2010;54(3):1111-1116. doi:10.1128/AAC.01183-09<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/20038614/pubmed" id="20038614" target="_blank">20038614</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32147665">
<a name="32147665"></a>Cunningham JM, Sachs KV, Allyn R. Cefepime-induced neurotoxicity presenting with nonconvulsive status epilepticus admitted as a stroke alert. <i>Am J Case Rep</i>. 2020;21:e921643. doi:10.12659/AJCR.921643<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/32147665/pubmed" id="32147665" target="_blank">32147665</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26846675">
<a name="26846675"></a>Descombes E, Martins F, Hemett OM, Erard V, Chuard C. Three-times-weekly, post-dialysis cefepime therapy in patients on maintenance hemodialysis: a retrospective study. <i>BMC Pharmacol Toxicol</i>. 2016;17:4. doi:10.1186/s40360-016-0048-y<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/26846675/pubmed" id="26846675" target="_blank">26846675</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23620467">
<a name="23620467"></a>Deshpande A, Pasupuleti V, Thota P, et al. Community-associated Clostridium difficile infection and antibiotics: a meta-analysis. <i>J Antimicrob Chemother</i>. 2013;68(9):1951-1961. doi:10.1093/jac/dkt129<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/23620467/pubmed" id="23620467" target="_blank">23620467</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36669519">
<a name="36669519"></a>de Wijkerslooth EML, Boerma EG, van Rossem CC, et al; APPIC Study Group. 2 days versus 5 days of postoperative antibiotics for complex appendicitis: a pragmatic, open-label, multicentre, non-inferiority randomised trial. <i>Lancet</i>. 2023;401(10374):366-376. doi:10.1016/S0140-6736(22)02588-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/36669519/pubmed" id="36669519" target="_blank">36669519</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Droege.1">
<a name="Droege.1"></a>Droege M, Van Fleet S, Healy D, et al. Continuous renal replacement therapy and flow rate influence on cefepime pharmacokinetics. <i>Crit Care Med</i>. 2013;41:12(suppl):PA244. doi:10.1097/01.ccm.0000440208.69019.76</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22298349">
<a name="22298349"></a>Durand-Maugard C, Lemaire-Hurtel AS, Gras-Champel V, et al. Blood and CSF monitoring of cefepime-induced neurotoxicity: nine case reports. <i>J Antimicrob Chemother</i>. 2012;67(5):1297-1299. doi:10.1093/jac/dks012<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/22298349/pubmed" id="22298349" target="_blank">22298349</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17426074">
<a name="17426074"></a>Ellis JM, Rivera L, Reyes G, et al. Cefepime cerebrospinal fluid concentrations in neonatal bacterial meningitis. <i>Ann Pharmacother</i>. 2007;41(5):900‐901.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/17426074/pubmed" id="17426074" target="_blank">17426074</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34599691">
<a name="34599691"></a>Evans L, Rhodes A, Alhazzani W, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. <i>Intensive Care Med</i>. 2021;47(11):1181-1247. doi:10.1007/s00134-021-06506-y 34599691<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/34599691/pubmed" id="34599691" target="_blank">34599691</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOO">
<a name="Expert.DOO"></a>Expert opinion. Senior Obesity Editorial Team: Jeffrey F. Barletta, PharmD, FCCM; Manjunath P. Pai, PharmD, FCP; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19729669">
<a name="19729669"></a>Flume PA, Mogayzel PJ Jr, Robinson KA, et al; Clinical Practice Guidelines for Pulmonary Therapies Committee. Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations. <i>Am J Respir Crit Care Med.</i> 2009;180(9):802-808. doi:10.1164/rccm.200812-1845PP<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/19729669/pubmed" id="19729669" target="_blank">19729669</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33480024">
<a name="33480024"></a>Fratoni AJ, Nicolau DP, Kuti JL. A guide to therapeutic drug monitoring of β-lactam antibiotics. <i>Pharmacotherapy</i>. 2021;41(2):220-233. doi:10.1002/phar.2505<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/33480024/pubmed" id="33480024" target="_blank">33480024</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21258094">
<a name="21258094"></a>Freifeld AG, Bow EJ, Sepkowitz KA, et al; Infectious Diseases Society of America. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America.<i> Clin Infect Dis.</i> 2011;52(4):e56-e93. doi:10.1093/cid/cir073<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/21258094/pubmed" id="21258094" target="_blank">21258094</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24200036">
<a name="24200036"></a>Fugate JE, Kalimullah EA, Hocker SE, Clark SL, Wijdicks EF, Rabinstein AA. Cefepime neurotoxicity in the intensive care unit: a cause of severe, underappreciated encephalopathy. <i>Crit Care</i>. 2013;17(6):R264. doi:10.1186/cc13094<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/24200036/pubmed" id="24200036" target="_blank">24200036</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31175111">
<a name="31175111"></a>Garin A, Bavozet F. Myoclonic status epilepticus induced by cefepime overdose requiring haemodialysis. <i>BMJ Case Rep</i>. 2019;12(6):e228108. doi:10.1136/bcr-2018-228108<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/31175111/pubmed" id="31175111" target="_blank">31175111</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10630824">
<a name="10630824"></a>Garrelts JC, Wagner DJ. The Pharmacokinetics, Safety, and Tolerance of Cefepime Administered as an Intravenous Bolus or as a Rapid Infusion. <i>Ann Pharmacother</i>. 1999;33(12):1258-1261.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/10630824/pubmed" id="10630824" target="_blank">10630824</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1804010">
<a name="1804010"></a>Gentry LO, Rodriguez-Gomez G. Randomized comparison of cefepime and ceftazidime for treatment of skin, surgical wound, and complicated urinary tract infections in hospitalized subjects. <i>Antimicrob Agents Chemother</i>. 1991;35(11):2371-2374.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/1804010/pubmed" id="1804010" target="_blank">1804010</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16119511">
<a name="16119511"></a>Georges B, Conil JM, Cougot P, et al. Cefepime in critically ill patients: continuous infusion vs. an intermittent dosing regimen. <i>Int J Clin Pharmacol Ther</i>. 2005;43(8):360-369. doi:10.5414/cpp43360<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/16119511/pubmed" id="16119511" target="_blank">16119511</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Goldenberg.1">
<a name="Goldenberg.1"></a>Goldenberg DL, Sexton DJ. Septic arthritis in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 10, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29090866">
<a name="29090866"></a>Gomi H, Solomkin JS, Schlossberg D, et al. Tokyo guidelines 2018: antimicrobial therapy for acute cholangitis and cholecystitis. <i>J Hepatobiliary Pancreat Sci</i>. 2018;25(1):3-16. doi:10.1002/jhbp.518<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/29090866/pubmed" id="29090866" target="_blank">29090866</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34469706">
<a name="34469706"></a>Goss CH, Heltshe SL, West NE, et al; STOP2 Investigators. A randomized clinical trial of antimicrobial duration for cystic fibrosis pulmonary exacerbation treatment. <i>Am J Respir Crit Care Med</i>. 2021;204(11):1295-1305. doi:10.1164/rccm.202102-0461OC<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/34469706/pubmed" id="34469706" target="_blank">34469706</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30925922">
<a name="30925922"></a>Guilhaumou R, Benaboud S, Bennis Y, et al. Optimization of the treatment with beta-lactam antibiotics in critically ill patients-guidelines from the French Society of Pharmacology and Therapeutics (Société Française de Pharmacologie et Thérapeutique-SFPT) and the French Society of Anaesthesia and Intensive Care Medicine (Société Française d'Anesthésie et Réanimation-SFAR). <i>Crit Care</i>. 2019;23(1):104. doi:10.1186/s13054-019-2378-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/30925922/pubmed" id="30925922" target="_blank">30925922</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Gupta.1">
<a name="Gupta.1"></a>Gupta K. Acute complicated urinary tract infection (including pyelonephritis) in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed December 16, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21292654">
<a name="21292654"></a>Gupta K, Hooton TM, Naber KG, et al; Infectious Diseases Society of America; European Society for Microbiology and Infectious Diseases. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. <i>Clin Infect Dis.</i> 2011;52(5):e103-e120. doi: 10.1093/cid/ciq257.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/21292654/pubmed" id="21292654" target="_blank">21292654</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29225828">
<a name="29225828"></a>Guzman-Limon M, Amatya S, Samuels J, Swinford R, Bhatnagar S, Samuel J. Cefepime-induced neurotoxicity in a pediatric patient on chronic hemodialysis: a case report. <i>Clin Case Rep</i>. 2017;5(12):1931-1933. doi:10.1002/ccr3.1217<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/29225828/pubmed" id="29225828" target="_blank">29225828</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Haase.1">
<a name="Haase.1"></a>Haase MR. Acute Bacterial Meningitis in Children. <i>J Pharm Pract</i>. 2004;17:392.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36081354">
<a name="36081354"></a>Hambrick HR, Pavia K, Tang Girdwood S, Lazear D, Taylor JM, Benoit S. Cefepime-associated neurotoxicity in a pediatric patient with stage V chronic kidney disease. <i>J Pharm Pract</i>. Published online September 8, 2022. doi:10.1177/08971900221125000<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/36081354/pubmed" id="36081354" target="_blank">36081354</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16533828">
<a name="16533828"></a>Han EE, Beringer PM, Falck P, et al. Pilot study of continuous infusion cefepime in adult patients with cystic fibrosis. <i>J Antimicrob Chemother</i>. 2006;57(5):1017‐1019.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/16533828/pubmed" id="16533828" target="_blank">16533828</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33097683">
<a name="33097683"></a>Haraszti S, Sendil S, Jensen N. Delayed presentation of acute generalized exanthematous pustulosis following treatment with cefepime in a patient with COVID-19 without the use of hydroxychloroquine. <i>Am J Case Rep</i>. 2020;21:e926901. doi:10.12659/AJCR.926901<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/33097683/pubmed" id="33097683" target="_blank">33097683</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hasbun.1">
<a name="Hasbun.1"></a>Hasbun R. Treatment of bacterial meningitis caused by specific pathogens in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 10, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19397464">
<a name="19397464"></a>Heintz BH, Matzke GR, Dager WE. Antimicrobial dosing concepts and recommendations for critically ill adult patients receiving continuous renal replacement therapy or intermittent hemodialysis. <i>Pharmacotherapy.</i> 2009;29(5):562-577.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/19397464/pubmed" id="19397464" target="_blank">19397464</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22146873">
<a name="22146873"></a>Hensgens MP, Goorhuis A, Dekkers OM, Kuijper EJ. Time interval of increased risk for Clostridium difficile infection after exposure to antibiotics. <i>J Antimicrob Chemother</i>. 2012;67(3):742-748. doi:10.1093/jac/dkr508<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/22146873/pubmed" id="22146873" target="_blank">22146873</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24956136">
<a name="24956136"></a>Hites M, Taccone FS, Wolff F, et al. Broad-spectrum β-lactams in obese non-critically ill patients. <i>Nutr Diabetes</i>. 2014;4(6):e119. doi:10.1038/nutd.2014.15<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/24956136/pubmed" id="24956136" target="_blank">24956136</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23147743">
<a name="23147743"></a>Hites M, Taccone FS, Wolff F, et al. Case-control study of drug monitoring of β-lactams in obese critically ill patients. <i>Antimicrob Agents Chemother</i>. 2013;57(2):708-715. doi:10.1128/AAC.01083-12<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/23147743/pubmed" id="23147743" target="_blank">23147743</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8150761">
<a name="8150761"></a>Hoepelman AI, Kieft H, Aoun M, et al. International comparative study of cefepime and ceftazidime in the treatment of serious bacterial infections. <i>J Antimicrob Chemother</i>. 1993;32(suppl B):175-186. doi:10.1093/jac/32.suppl_b.175<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/8150761/pubmed" id="8150761" target="_blank">8150761</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28111294">
<a name="28111294"></a>Huwyler T, Lenggenhager L, Abbas M, et al. Cefepime plasma concentrations and clinical toxicity: a retrospective cohort study. <i>Clin Microbiol Infect</i>. 2017;23(7):454-459. doi:10.1016/j.cmi.2017.01.005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/28111294/pubmed" id="28111294" target="_blank">28111294</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29260037">
<a name="29260037"></a>Isitan C, Ferree A, Hohler AD. Cefepime induced neurotoxicity: a case series and review of the literature. <i>eNeurologicalSci</i>. 2017;8:40-43. doi:10.1016/j.ensci.2017.08.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/29260037/pubmed" id="29260037" target="_blank">29260037</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29746711">
<a name="29746711"></a>Jang SM, Gharibian KN, Lewis SJ, Fissell WH, Tolwani AJ, Mueller BA. A Monte Carlo simulation approach for beta-lactam dosing in critically ill patients receiving prolonged intermittent renal replacement therapy. <i>J Clin Pharmacol</i>. 2018;58(10):1254-1265. doi: 10.1002/jcph.1137<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/29746711/pubmed" id="29746711" target="_blank">29746711</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8150758">
<a name="8150758"></a>Jauregui L, Matzke D, Scott M, Minns P, Hageage G. Cefepime as treatment for osteomyelitis and other severe bacterial infections. <i>J Antimicrob Chemother.</i> 1993;32(suppl B):141-149. doi: 10.1093/jac/32.suppl_b.141<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/8150758/pubmed" id="8150758" target="_blank">8150758</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27246236">
<a name="27246236"></a>Jonckheere S, De Neve N, De Beenhouwer H, et al. A model-based analysis of the predictive performance of different renal function markers for cefepime clearance in the ICU.<i> J Antimicrob Chemother</i>. 2016;71(9):2538-2546. doi:10.1093/jac/dkw171<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/27246236/pubmed" id="27246236" target="_blank">27246236</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34094864">
<a name="34094864"></a>Jones BM, Murray EY, Crosby C, Rojas S, Bland CM. Eosinophilic pneumonia caused by cefepime: a case report and review. <i>IDCases</i>. 2021;25:e01166. doi:10.1016/j.idcr.2021.e01166<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/34094864/pubmed" id="34094864" target="_blank">34094864</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27418577">
<a name="27418577"></a>Kalil AC, Metersky ML, Klompas M, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. <i>Clin Infect Dis</i>. Published online July 14, 2016. doi:10.1093/cid/ciw353<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/27418577/pubmed" id="27418577" target="_blank">27418577</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kanj.3">
<a name="Kanj.3"></a>Kanj SS, Sexton DJ. Pseudomonas aeruginosa bacteremia and endocarditis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 9, 2023a.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kanj.1">
<a name="Kanj.1"></a>Kanj SS, Sexton DJ. Pseudomonas aeruginosa skin and soft tissue infections. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 9, 2023b.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32699729">
<a name="32699729"></a>Khorasani-Zadeh A, Greca I, Gada K. Cefepime-induced seizures: the overlooked outpatient adverse reaction. <i>Cureus</i>. 2020;12(7):e9268. doi:10.7759/cureus.9268<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/32699729/pubmed" id="32699729" target="_blank">32699729</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24649471">
<a name="24649471"></a>Kim A, Kim JE, Paek YM, et al. Cefepime-induced non-convulsive status epilepticus (NCSE). <i>J Epilepsy Res</i>. 2013;3(1):39-41. doi:10.14581/jer.13008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/24649471/pubmed" id="24649471" target="_blank">24649471</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Klompas.1">
<a name="Klompas.1"></a>Klompas M. Treatment of hospital-acquired and ventilator-associated pneumonia in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 15, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29970977">
<a name="29970977"></a>Knoderer CA, Kaylor DM, Toth ME, Malloy KM, Nichols KR. Characterization of the clinical outcomes with cefepime in a neonatal intensive care unit: a retrospective cohort study. <i>J Pediatr Pharmacol Ther</i>. 2018;23(3):209‐214. doi:10.5863/1551-6776-23.3.209<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/29970977/pubmed" id="29970977" target="_blank">29970977</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20435246">
<a name="20435246"></a>Koomanachai P, Bulik CC, Kuti JL, Nicolau DP. Pharmacodynamic modeling of intravenous antibiotics against gram-negative bacteria collected in the United States.<i> Clin Ther.</i> 2010;32(4):766-779. doi:10.1016/j.clinthera.2010.04.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/20435246/pubmed" id="20435246" target="_blank">20435246</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20189057">
<a name="20189057"></a>Kuti JL, Nicolau DP. Optimal cefepime and meropenem dosing for ventilator-associated pneumonia patients with reduced renal function: an update to our clinical pathway. <i>J Crit Care</i>. 2010;25(1):155-156. doi:10.1016/j.jcrc.2010.01.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/20189057/pubmed" id="20189057" target="_blank">20189057</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20625153">
<a name="20625153"></a>Lamoth F, Buclin T, Pascual A, et al. High cefepime plasma concentrations and neurological toxicity in febrile neutropenic patients with mild impairment of renal function. <i>Antimicrob Agents Chemother</i>. 2010;54(10):4360-4367. doi:10.1128/AAC.01595-08<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/20625153/pubmed" id="20625153" target="_blank">20625153</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33382398">
<a name="33382398"></a>Lee JD, Heintz BH, Mosher HJ, Livorsi DJ, Egge JA, Lund BC. Risk of acute kidney injury and Clostridioides difficile infection with piperacillin/tazobactam, cefepime, and meropenem with or without vancomycin. <i>Clin Infect Dis</i>. 2021;73(7):e1579-e1586. doi:10.1093/cid/ciaa1902<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/33382398/pubmed" id="33382398" target="_blank">33382398</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25749765">
<a name="25749765"></a>Lee SH, Kim MH, Lee K, Jo EJ, Park HK. Hypersensitivity pneumonitis caused by cephalosporins with identical R1 side chains. <i>Allergy Asthma Immunol Res</i>. 2015;7(5):518-522. doi:10.4168/aair.2015.7.5.518<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/25749765/pubmed" id="25749765" target="_blank">25749765</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28459614">
<a name="28459614"></a>Lehrnbecher T, Robinson P, Fisher B, et al. Guideline for the management of fever and neutropenia in children with cancer and hematopoietic stem-cell transplantation recipients: 2017 update. <i>J Clin Oncol</i>. 2017;35(18):2082-2094. doi:10.1200/JCO.2016.71.7017<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/28459614/pubmed" id="28459614" target="_blank">28459614</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27282851">
<a name="27282851"></a>Li PK, Szeto CC, Piraino B, et al. ISPD peritonitis recommendations: 2016 update on prevention and treatment [published correction appears in <i>Perit Dial Int</i>. 2018;38(4):313]. <i>Perit Dial Int</i>. 2016;36(5):481-508. doi:10.3747/pdi.2016.00078<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/27282851/pubmed" id="27282851" target="_blank">27282851</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21986835">
<a name="21986835"></a>Lim PP, Chong CP, Aziz NA. Cefepime-associated thrombocytopenia in a critically ill patient. <i>Int J Clin Pharm</i>. 2011;33(6):902-904. doi:10.1007/s11096-011-9571-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/21986835/pubmed" id="21986835" target="_blank">21986835</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18452417">
<a name="18452417"></a>Lima-Rogel V, Medina-Rojas EL, Del Carmen Milán-Segovia R, et al. Population Pharmacokinetics of Cefepime in Neonates With Severe Nosocomial Infections. <i>J Clin Pharm Ther</i>. 2008;33(3):295-306.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/18452417/pubmed" id="18452417" target="_blank">18452417</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22619242">
<a name="22619242"></a>Lipsky BA, Berendt AR, Cornia PB, et al; Infectious Diseases Society of America. 2012 Infectious Diseases Society of America clinical practice guideline for the diagnosis and treatment of diabetic foot infections. <i>Clin Infect Dis.</i> 2012;54(12):e132-e173. doi:10.1093/cid/cis346<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/22619242/pubmed" id="22619242" target="_blank">22619242</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30412900">
<a name="30412900"></a>Lizarraga KJ, Heros DO, Adams D, Lang AE, Kanner AM. Opsoclonus-myoclonus-encephalopathy induced by cefepime. <i>J Neurol Sci</i>. 2019;396:33-35. doi:10.1016/j.jns.2018.10.028<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/30412900/pubmed" id="30412900" target="_blank">30412900</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16945055">
<a name="16945055"></a>Lodise TP, Lomaestro BM, Drusano GL; Society of Infectious Diseases Pharmacists. Application of antimicrobial pharmacodynamic concepts into clinical practice: focus on beta-lactam antibiotics: insights from the Society of Infectious Diseases Pharmacists. <i>Pharmacotherapy</i>. 2006;26(9):1320-1332. doi:10.1592/phco.26.9.1320<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/16945055/pubmed" id="16945055" target="_blank">16945055</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35971666">
<a name="35971666"></a>Maan G, Keitoku K, Kimura N, et al. Cefepime-induced neurotoxicity: systematic review. <i>J Antimicrob Chemother</i>. 2022;77(11):2908-2921. doi:10.1093/jac/dkac271<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/35971666/pubmed" id="35971666" target="_blank">35971666</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24342637">
<a name="24342637"></a>MacVane SH, Kuti JL, Nicolau DP. Clinical pharmacodynamics of antipseudomonal cephalosporins in patients with ventilator-associated pneumonia. <i>Antimicrob Agents Chemother</i>. 2014a;58(3):1359-1364. doi:10.1128/AAC.01463-13<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/24342637/pubmed" id="24342637" target="_blank">24342637</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24359838">
<a name="24359838"></a>MacVane SH, Kuti JL, Nicolau DP. Prolonging β-lactam infusion: a review of the rationale and evidence, and guidance for implementation. <i>Int J Antimicrob Agents</i>. 2014b;43(2):105-113. doi:10.1016/j.ijantimicag.2013.10.021<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/24359838/pubmed" id="24359838" target="_blank">24359838</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34098807">
<a name="34098807"></a>Malhotra K, Fazylov R, Friedman-Jakubovics M. A case-report of drug-induced mixed liver injury resulting from cefepime exposure. <i>J Pharm Pract</i>. 2023;36(1):164-167. doi:10.1177/08971900211015046<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/34098807/pubmed" id="34098807" target="_blank">34098807</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19902990">
<a name="19902990"></a>Malincarne L, Francisci D, Martinelli L, Masini G, Baldelli F. A case of severe cefepime-related neutropenia in a 15-year-old patient. <i>Scand J Infect Dis</i>. 2010;42(2):156-157. doi:10.3109/00365540903380503<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/19902990/pubmed" id="19902990" target="_blank">19902990</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11600370">
<a name="11600370"></a>Malone RS, Fish DN, Abraham E, Teitelbaum I. Pharmacokinetics of cefepime during continuous renal replacement therapy in critically ill patients. <i>Antimicrob Agents Chemother</i>. 2001;45(11):3148-3155. doi:10.1128/AAC.45.11.3148-3155.2001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/11600370/pubmed" id="11600370" target="_blank">11600370</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29987068">
<a name="29987068"></a>Mancini A, Todd L. Inconsistencies in ISPD peritonitis recommendations: 2016 update on prevention and treatment and the ISPD catheter-related infection recommendations: 2017 update. <i>Perit Dial Int</i>. 2018;38(4):309-310. doi:10.3747/pdi.2018.00026<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/29987068/pubmed" id="29987068" target="_blank">29987068</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28692440">
<a name="28692440"></a>Marco-Del Río J, Domingo-Chiva E, Cuesta-Montero P, Valladolid-Walsh A, García-Martínez EM. Cefepime associated with phenytoin induced Stevens-Johnson syndrome. <i>Am J Ther</i>. 2017;24(4):e481-e484. doi:10.1097/MJT.0000000000000520<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/28692440/pubmed" id="28692440" target="_blank">28692440</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34278415">
<a name="34278415"></a>Marsh K, Ahmed N, Decano A, et al. Safety of intravenous push administration of beta-lactams within a healthcare system. <i>Am J Health Syst Pharm</i>. 2020;77(9):701-708. doi:10.1093/ajhp/zxaa044<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/34278415/pubmed" id="34278415" target="_blank">34278415</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11498064">
<a name="11498064"></a>Martínez-Rodríguez JE, Barriga FJ, Santamaria J, et al. Nonconvulsive status epilepticus associated with cephalosporins in patients with renal failure. <i>Am J Med</i>. 2001;111(2):115-119. doi:10.1016/s0002-9343(01)00767-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/11498064/pubmed" id="11498064" target="_blank">11498064</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Maxipime.1">
<a name="Maxipime.1"></a>Maxipime (cefepime) [prescribing information]. Lake Forest, IL: Hospira Inc; August 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28085573">
<a name="28085573"></a>Mazuski JE, Tessier JM, May AK, et al. The Surgical Infection Society revised guidelines on the management of intra-abdominal infection. <i>Surg Infect (Larchmt).</i> 2017;18(1):1-76. doi:10.1089/sur.2016.261<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/28085573/pubmed" id="28085573" target="_blank">28085573</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29462280">
<a name="29462280"></a>McDonald LC, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). <i>Clin Infect Dis</i>. 2018;66(7):e1-e48. doi:10.1093/cid/cix1085<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/29462280/pubmed" id="29462280" target="_blank">29462280</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29095181">
<a name="29095181"></a>McLaughlin JM, Scott RA, Koenig SL, Mueller SW. Intravenous push cephalosporin antibiotics in the emergency department: a practice improvement project. <i>Adv Emerg Nurs J</i>. 2017;39(4):295-299. doi:10.1097/TME.0000000000000160<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/29095181/pubmed" id="29095181" target="_blank">29095181</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26011581">
<a name="26011581"></a>Medrano-Casique N, Tong HY, Borobia AM, Carcas AJ, Frías J, Ramírez E. Non-chemotherapy-induced agranulocytosis detected by a prospective pharmacovigilance program in a tertiary hospital. <i>Basic Clin Pharmacol Toxicol</i>. 2015;117(6):399-408. doi:10.1111/bcpt.12418<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/26011581/pubmed" id="26011581" target="_blank">26011581</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28869666">
<a name="28869666"></a>Meng L, Mui E, Holubar MK, Deresinski SC. Comprehensive guidance for antibiotic dosing in obese adults. <i>Pharmacotherapy</i>. 2017;37(11):1415-1431. doi:10.1002/phar.2023<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/28869666/pubmed" id="28869666" target="_blank">28869666</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19489710">
<a name="19489710"></a>Mermel LA, Allon M, Bouza E, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the Infectious Diseases Society of America [published corrections appear in <i>Clin Infect Dis.</i> 2010;50(7):1079; <i>Clin Infect Dis.</i> 2010;50(3):457]. <i>Clin Infect Dis.</i> 2009;49(1):1-45. doi:10.1086/599376<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/19489710/pubmed" id="19489710" target="_blank">19489710</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31573350">
<a name="31573350"></a>Metlay JP, Waterer GW, Long AC, et al. Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. <i>Am J Resp Crit Care Med</i>. 2019;200(7):e45-e67. doi:10.1164/rccm.201908-1581ST<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/31573350/pubmed" id="31573350" target="_blank">31573350</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31699837">
<a name="31699837"></a>Middleton PG, Gade EJ, Aguilera C, et al. ERS/TSANZ Task Force Statement on the management of reproduction and pregnancy in women with airways diseases. <i>Eur Respir J</i>. 2020;55(2):1901208. doi:10.1183/13993003.01208-2019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/31699837/pubmed" id="31699837" target="_blank">31699837</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Moehring.1">
<a name="Moehring.1"></a>Moehring R, Anderson DJ. Gram-negative bacillary bacteremia in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 9, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Moehring.2">
<a name="Moehring.2"></a>Moehring R, Sarubbi C. Prolonged infusions of beta-lactam antibiotics. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 13, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26498903">
<a name="26498903"></a>Molloy L, Nichols K. Infectious diseases pharmacotherapy for children with cystic fibrosis. <i>J Pediatr Health Care</i>. 2015;29(6):565‐580.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/26498903/pubmed" id="26498903" target="_blank">26498903</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35359889">
<a name="35359889"></a>Morales Junior R, Pereira GO, Tiguman GMB, et al. Beta-lactams therapeutic monitoring in septic children-what target are we aiming for? A scoping review. <i>Front Pediatr</i>. 2022;10:777854. doi:10.3389/fped.2022.777854<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/35359889/pubmed" id="35359889" target="_blank">35359889</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17323865">
<a name="17323865"></a>Moreno E, Dávila I, Laffond E, et al. Selective immediate hypersensitivity to cefepime. <i>J Investig Allergol Clin Immunol</i>. 2007;17(1):52-54.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/17323865/pubmed" id="17323865" target="_blank">17323865</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NICE.2014">
<a name="NICE.2014"></a>National Institute for Health and Care Excellence. Drug allergy: diagnosis and management. Published September 3, 2014. Accessed October 2, 2020. https://www.nice.org.uk/guidance/cg183
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35968536">
<a name="35968536"></a>Nguyen C, Clegg T, Kumar A, Paudel S. Cefepime-induced nonconvulsive status epilepticus in a pediatric patient with normal renal function. <i>Child Neurol Open</i>. 2022;9:2329048X221119575. doi:10.1177/2329048X221119575<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/35968536/pubmed" id="35968536" target="_blank">35968536</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19188394">
<a name="19188394"></a>Nicasio AM, Ariano RE, Zelenitsky SA, et al. Population pharmacokinetics of high-dose, prolonged-infusion cefepime in adult critically ill patients with ventilator-associated pneumonia. <i>Antimicrob Agents Chemother.</i> 2009;53(4):1476-1481. doi: 10.1128/AAC.01141-08.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/19188394/pubmed" id="19188394" target="_blank">19188394</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19427167">
<a name="19427167"></a>Nicasio AM, Eagye KJ, Nicolau DP, Shore E, Palter M, et al. Pharmacodynamic-based clinical pathway for empiric antibiotic choice in patients with ventilator-associated pneumonia. <i>J Crit Care</i>. 2010;25(1):69-77. doi:10.1016/j.jcrc.2009.02.014<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/19427167/pubmed" id="19427167" target="_blank">19427167</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25614528">
<a name="25614528"></a>Nichols KR, Karmire LC, Cox EG, Kays MB, Knoderer CA. Implementing extended-infusion cefepime as standard of care in a children's hospital: a prospective descriptive study. <i>Ann Pharmacother</i>. 2015;49(4):419‐426.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/25614528/pubmed" id="25614528" target="_blank">25614528</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15565489">
<a name="15565489"></a>Ohtaki K, Matsubara K, Fujimaru S, et al. Cefoselis, a beta-lactam antibiotic, easily penetrates the blood-brain barrier and causes seizure independently by glutamate release. <i>J Neural Transm (Vienna)</i>. 2004;111(12):1523-1535. doi:10.1007/s00702-004-0177-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/15565489/pubmed" id="15565489" target="_blank">15565489</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14763949">
<a name="14763949"></a>Orhan F, Odemis E, Yaris N, et al. A case of IgE-mediated hypersensitivity to cefepime. <i>Allergy</i>. 2004;59(2):239-241. doi:10.1046/j.1398-9995.2003.00376.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/14763949/pubmed" id="14763949" target="_blank">14763949</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23223583">
<a name="23223583"></a>Osmon DR, Berbari EF, Berendt AR, et al; Infectious Diseases Society of America. Diagnosis and management of prosthetic joint infection: clinical practice guideline by the Infectious Diseases Society of America. <i>Clin Infect Dis.</i> 2013;56(1):e1-e25. doi:10.1093/cid/cis803<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/23223583/pubmed" id="23223583" target="_blank">23223583</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Osmon.1">
<a name="Osmon.1"></a>Osmon DR, Tande AJ. Osteomyelitis in adults: treatment. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 10, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33614301">
<a name="33614301"></a>Oyenuga M, Oyenuga A, Rauf A, Balogun O, Singh N. New onset non-convulsive status epilepticus despite cefepime renal dose adjustment. <i>Cureus</i>. 2021;13(1):e12689. doi:10.7759/cureus.12689<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/33614301/pubmed" id="33614301" target="_blank">33614301</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19996590">
<a name="19996590"></a>Ozbek B, Otuk G. Post-antibiotic effect of levofloxacin and tobramycin alone or in combination with cefepime against <i>Pseudomonas aeruginosa</i>. <i>Chemotherapy</i>. 2009;55(6):446-450. doi:10.1159/000265128<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/19996590/pubmed" id="19996590" target="_blank">19996590</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20418070">
<a name="20418070"></a>Ozyuncu O, Nemutlu E, Katlan D, Kir S, Beksac MS. Maternal and fetal blood levels of moxifloxacin, levofloxacin, cefepime and cefoperazone. <i>Int J Antimicrob Agents</i>. 2010;36(2):175‐178. doi:10.1016/j.ijantimicag.2010.03.011<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/20418070/pubmed" id="20418070" target="_blank">20418070</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26942733">
<a name="26942733"></a>Panchaud A, Di Paolo ER, Koutsokera A, et al. Safety of drugs during pregnancy and breastfeeding in cystic fibrosis patients. <i>Respiration</i>. 2016;91(4):333‐348. doi:10.1159/000444088<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/26942733/pubmed" id="26942733" target="_blank">26942733</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29137682">
<a name="29137682"></a>Payne LE, Gagnon DJ, Riker RR, et al. Cefepime-induced neurotoxicity: a systematic review. <i>Crit Care</i>. 2017;21(1):276. doi:10.1186/s13054-017-1856-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/29137682/pubmed" id="29137682" target="_blank">29137682</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Pemberton.1">
<a name="Pemberton.1"></a>Pemberton JH. Acute colonic diverticulitis: medical management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 5, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22440135">
<a name="22440135"></a>Perez KK, Hughes DW, Maxwell PR, Green K, Lewis JS 2nd. Cefepime for gram-negative bacteremia in long-term hemodialysis: a single-center experience. <i>Am J Kidney Dis.</i> 2012; 59(5):740-742. doi:10.1053/j.ajkd.2012.01.012<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/22440135/pubmed" id="22440135" target="_blank">22440135</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31549737">
<a name="31549737"></a>Philpott CD, Droege CA, Droege ME, et al. Pharmacokinetics and pharmacodynamics of extended-infusion cefepime in critically ill patients receiving continuous renal replacement therapy: a prospective, open-label study. <i>Pharmacotherapy</i>. 2019;39(11):1066-1076. doi:10.1002/phar.2332<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/31549737/pubmed" id="31549737" target="_blank">31549737</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22346306">
<a name="22346306"></a>Prescott WA Jr, Gentile AE, Nagel JL, Pettit RS. Continuous-infusion antipseudomonal Beta-lactam therapy in patients with cystic fibrosis. <i>P T</i>. 2011;36(11):723‐763.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/22346306/pubmed" id="22346306" target="_blank">22346306</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28775112">
<a name="28775112"></a>Qadri I, Zeng X, Guo R, Koratala A. Acute interstitial nephritis and DRESS syndrome without eosinophilia associated with cefepime. <i>BMJ Case Rep</i>. 2017;2017:bcr2017221401. doi:10.1136/bcr-2017-221401<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/28775112/pubmed" id="28775112" target="_blank">28775112</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32561442">
<a name="32561442"></a>Ramirez JA, Musher DM, Evans SE, et al. Treatment of community-acquired pneumonia in immunocompromised adults: a consensus statement regarding initial strategies. <i>Chest</i>. 2020;158(5):1896-1911. doi:10.1016/j.chest.2020.05.598<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/32561442/pubmed" id="32561442" target="_blank">32561442</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9257761">
<a name="9257761"></a>Reed MD, Yamashita TS, Knupp CK, Veazey JM Jr, Blumer JL. Pharmacokinetics of intravenously and intramuscularly administered cefepime in infants and children. <i>Antimicrob Agents Chemother.</i> 1997;41(8):1783-1787. doi:10.1128/AAC.41.8.1783<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/9257761/pubmed" id="9257761" target="_blank">9257761</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-manufacturer.1">
<a name="manufacturer.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28668694">
<a name="28668694"></a>Rhodes NJ, Grove ME, Kiel PJ, et al. Population pharmacokinetics of cefepime in febrile neutropenia: implications for dose-dependent susceptibility and contemporary dosing regimens. <i>Int J Antimicrob Agents</i>. 2017;50(3):482-486. doi:10.1016/j.ijantimicag.2017.04.008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/28668694/pubmed" id="28668694" target="_blank">28668694</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12627928">
<a name="12627928"></a>Rhoney DH, Tam VH, Parker D Jr, McKinnon PS, Coplin WM. Disposition of cefepime in the central nervous system of patients with external ventricular drains. <i>Pharmacotherapy</i>. 2003;23(3):310-314. doi:10.1592/phco.23.3.310.32108<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/12627928/pubmed" id="12627928" target="_blank">12627928</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22249886">
<a name="22249886"></a>Rich BS, Keel R, Ho VP, et al. Cefepime dosing in the morbidly obese patient population. <i>Obes Surg</i>. 2012;22(3):465-471. doi:10.1007/s11695-011-0586-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/22249886/pubmed" id="22249886" target="_blank">22249886</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29337797">
<a name="29337797"></a>Roberts JA. Beta-lactam therapeutic drug monitoring in the critically ill children: big solution for infections in small people?. <i>Crit Care Med</i>. 2018;46(2):335-337. doi:10.1097/CCM.0000000000002862<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/29337797/pubmed" id="29337797" target="_blank">29337797</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24429437">
<a name="24429437"></a>Roberts JA, Paul SK, Akova M, et al; DALI Study. DALI: defining antibiotic levels in intensive care unit patients: are current β-lactam antibiotic doses sufficient for critically ill patients? <i>Clin Infect Dis</i>. 2014;58(8):1072-1083. doi:10.1093/cid/ciu027<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/24429437/pubmed" id="24429437" target="_blank">24429437</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25930196">
<a name="25930196"></a>Romano A, Gaeta F, Valluzzi RL, et al. IgE-mediated hypersensitivity to cephalosporins: cross-reactivity and tolerability of alternative cephalosporins. <i>J Allergy Clin Immunol</i>. 2015;136(3):685-691.e3. doi:10.1016/j.jaci.2015.03.012<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/25930196/pubmed" id="25930196" target="_blank">25930196</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27016799">
<a name="27016799"></a>Romano A, Gaeta F, Valluzzi RL, Maggioletti M, Caruso C, Quaratino D. Cross-reactivity and tolerability of aztreonam and cephalosporins in subjects with a T cell-mediated hypersensitivity to penicillins. <i>J Allergy Clin Immunol</i>. 2016;138(1):179-186. doi:10.1016/j.jaci.2016.01.025<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/27016799/pubmed" id="27016799" target="_blank">27016799</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29408440">
<a name="29408440"></a>Romano A, Valluzzi RL, Caruso C, Maggioletti M, Quaratino D, Gaeta F. Cross-reactivity and tolerability of cephalosporins in patients with IgE-mediated hypersensitivity to penicillins. <i>J Allergy Clin Immunol Pract</i>. 2018;6(5):1662-1672. doi:10.1016/j.jaip.2018.01.020<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/29408440/pubmed" id="29408440" target="_blank">29408440</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16943209">
<a name="16943209"></a>Roos JF, Bulitta J, Lipman J, Kirkpatrick CM. Pharmacokinetic-pharmacodynamic rationale for cefepime dosing regimens in intensive care units.<i> J Antimicrob Chemother.</i> 2006;58(5):987-993. doi:10.1093/jac/dkl349<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/16943209/pubmed" id="16943209" target="_blank">16943209</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7785999">
<a name="7785999"></a>Sáez-Llorens X, Castaño E, García R, et al. Prospective randomized comparison of cefepime and cefotaxime for treatment of bacterial meningitis in infants and children. <i>Antimicrob Agents Chemother</i>. 1995;39(4):937‐940. doi:10.1128/AAC.39.4.937<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/7785999/pubmed" id="7785999" target="_blank">7785999</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11303850">
<a name="11303850"></a>Sáez-Llorens X, O'Ryan M. Cefepime in the empiric treatment of meningitis in children. <i>Pediatr Infect Dis J</i>. 2001;20(3):356‐361.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/11303850/pubmed" id="11303850" target="_blank">11303850</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31660362">
<a name="31660362"></a>Santibañez M, Bunnell K, Harrington A, Bleasdale S, Wenzler E. Association between estimated pharmacokinetic/pharmacodynamic predictions of efficacy and observed clinical outcomes in obese and nonobese patients with <i>Enterobacteriaceae</i> bloodstream infections. <i>Open Forum Infect Dis</i>. 2019;6(10):ofz400. doi:10.1093/ofid/ofz400<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/31660362/pubmed" id="31660362" target="_blank">31660362</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28484510">
<a name="28484510"></a>Sartelli M, Catena F, Abu-Zidan FM, et al. Management of intra-abdominal infections: recommendations by the WSES 2016 consensus conference. <i>World J Emerg Surg</i>. Published online May 4, 2017. doi:10.1186/s13017-017-0132-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/28484510/pubmed" id="28484510" target="_blank">28484510</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25992746">
<a name="25992746"></a>Sawyer RG, Claridge JA, Nathens AB, et al; STOP-IT Trial Investigators. Trial of short-course antimicrobial therapy for intraabdominal infection. <i>N Engl J Med.</i> 2015;372(21):1996-2005. doi:10.1056/NEJMoa1411162<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/25992746/pubmed" id="25992746" target="_blank">25992746</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10853879">
<a name="10853879"></a>Schmaldienst S, Traunmüller F, Burgmann H, et al. Multiple-dose pharmacokinetics of cefepime in long-term hemodialysis with high-flux membranes. <i>Eur J Clin Pharmacol</i>. 2000;56(1):61-64. doi: 10.1007/s002280050721.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/10853879/pubmed" id="10853879" target="_blank">10853879</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7727671">
<a name="7727671"></a>Schrank JH Jr, Kelly JW, McAllister CK. Randomized comparison of cefepime and ceftazidime for treatment of hospitalized patients with gram-negative bacteremia. <i>Clin Infect Dis.</i> 1995;20(1):56-58. doi:10.1093/clinids/20.1.56<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/7727671/pubmed" id="7727671" target="_blank">7727671</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-sexton.2019a">
<a name="sexton.2019a"></a>Sexton DJ, Sampson JH. Intracranial epidural abscess. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed September 16, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-sexton.2019b">
<a name="sexton.2019b"></a>Sexton DJ, Sampson JH. Spinal epidural abscess. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 10, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32131755">
<a name="32131755"></a>Shah KJ, Cherabuddi K, Pressly KB, Wright KL, Shukla A. Clostridioides difficile associated peritonitis in peritoneal dialysis patients - a case series based review of an under-recognized entity with therapeutic challenges. <i>BMC Nephrol</i>. 2020;21(1):76. doi:10.1186/s12882-020-01734-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/32131755/pubmed" id="32131755" target="_blank">32131755</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33717772">
<a name="33717772"></a>Shah S, Bland S. Cefepime-induced encephalopathy with seizures in a pediatric patient with end-stage renal disease rapidly reversed by high-efficiency hemodialysis. <i>Cureus</i>. 2021;13(3):e13842. doi:10.7759/cureus.13842<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/33717772/pubmed" id="33717772" target="_blank">33717772</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29053792">
<a name="29053792"></a>Shane AL, Mody RK, Crump JA, et al. 2017 Infectious Diseases Society of America clinical practice guidelines for the diagnosis and management of infectious diarrhea. <i>Clin Infect Dis</i>. 2017;65(12):e45-e80. doi:10.1093/cid/cix669<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/29053792/pubmed" id="29053792" target="_blank">29053792</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27082510">
<a name="27082510"></a>Shaw AR, Chaijamorn W, Mueller BA. We underdose antibiotics in patients on CRRT. <i>Semin Dial</i>. 2016;29(4):278-280. doi:10.1111/sdi.12496<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/27082510/pubmed" id="27082510" target="_blank">27082510</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26810655">
<a name="26810655"></a>Shoji K, Bradley JS, Reed MD, van den Anker JN, Domonoske C, Capparelli EV. Population pharmacokinetic assessment and pharmacodynamic implications of pediatric cefepime dosing for susceptible-dose-dependent organisms. <i>Antimicrob Agents Chemother</i>. 2016;60(4):2150‐2156.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/26810655/pubmed" id="26810655" target="_blank">26810655</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36921180">
<a name="36921180"></a>Silva AMPSD, Barbosa LC, Marques LMA, et al. A case-control study of Clostridioides difficile symptomatic infections in a pediatric cancer hospital. <i>Rev Paul Pediatr</i>. 2023;41:e2022117. doi:10.1590/1984-0462/2023/41/2022117<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/36921180/pubmed" id="36921180" target="_blank">36921180</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Simon.1">
<a name="Simon.1"></a>Simon RH. Cystic fibrosis: Management of pulmonary exacerbations. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 9, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26897754">
<a name="26897754"></a>So W, Kuti JL, Shepard A, Nugent J, Nicolau DP. Tissue penetration and exposure of cefepime in patients with diabetic foot infections. <i>Int J Antimicrob Agents</i>. 2016;47(3):247-248. doi:10.1016/j.ijantimicag.2016.01.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/26897754/pubmed" id="26897754" target="_blank">26897754</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20034345">
<a name="20034345"></a>Solomkin JS, Mazuski JE, Bradley JS, et al. Diagnosis and management of complicated intra-abdominal infections in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America [published correction appears in <i>Clin Infect Dis</i>. 2010; 50(12):1695]. <i>Clin Infect Dis.</i> 2010;50(2):133-164. doi:10.1086/649554<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/20034345/pubmed" id="20034345" target="_blank">20034345</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18175786">
<a name="18175786"></a>Sonck J, Laureys G, Verbeelen D. The neurotoxicity and safety of treatment with cefepime in patients with renal failure. <i>Nephrol Dial Transplant</i>. 2008;23(3):966-970. doi:10.1093/ndt/gfm713<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/18175786/pubmed" id="18175786" target="_blank">18175786</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-southwick.2020">
<a name="southwick.2020"></a>Southwick FS. Treatment and prognosis of bacterial brain abscess. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 22, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30147136">
<a name="30147136"></a>Spencer S, Ipema H, Hartke P, et al. Intravenous push administration of antibiotics: literature and considerations. <i>Hosp Pharm</i>. 2018;53(3):157-169. doi:10.1177/0018578718760257<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/30147136/pubmed" id="30147136" target="_blank">30147136</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24947530">
<a name="24947530"></a>Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2014;59(2):147-59. doi:10.1093/cid/ciu296<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/24947530/pubmed" id="24947530" target="_blank">24947530</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21653301">
<a name="21653301"></a>Stevens V, Dumyati G, Fine LS, Fisher SG, van Wijngaarden E. Cumulative antibiotic exposures over time and the risk of Clostridium difficile infection. <i>Clin Infect Dis</i>. 2011;53(1):42-48. doi:10.1093/cid/cir301<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/21653301/pubmed" id="21653301" target="_blank">21653301</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30718247">
<a name="30718247"></a>Stitt G, Morris J, Schmees L, Angelo J, Akcan Arikan A. Cefepime pharmacokinetics in critically ill pediatric patients receiving continuous renal replacement therapy. <i>Antimicrob Agents Chemother</i>. 2019;63(4):e02006-18. doi:10.1128/AAC.02006-18<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/30718247/pubmed" id="30718247" target="_blank">30718247</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29905577">
<a name="29905577"></a>Subedi A, Songmen S, Manchala V, Mattana J. Cefepime-induced neurotoxicity: an underappreciated cause of encephalopathy. <i>Am J Ther</i>. 2019;26(4):e547-e548. doi:10.1097/MJT.0000000000000801<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/29905577/pubmed" id="29905577" target="_blank">29905577</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12871648">
<a name="12871648"></a>Sugimoto M, Uchida I, Mashimo T, et al. Evidence for the involvement of GABA(A) receptor blockade in convulsions induced by cephalosporins. <i>Neuropharmacology</i>. 2003;45(3):304-314. doi:10.1016/s0028-3908(03)00188-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/12871648/pubmed" id="12871648" target="_blank">12871648</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23529866">
<a name="23529866"></a>Sullins AK, Abdel-Rahman SM. Pharmacokinetics of antibacterial agents in the CSF of children and adolescents. <i>Paediatr Drugs</i>. 2013;15(2):93‐117<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/23529866/pubmed" id="23529866" target="_blank">23529866</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28738848">
<a name="28738848"></a>Su TY, Ye JJ, Yang CC, Huang CT, Chia JH, Lee MH. Influence of borderline cefepime MIC on the outcome of cefepime-susceptible Pseudomonas aeruginosa bacteremia treated with a maximal cefepime dose: a hospital-based retrospective study.<i> Ann Clin Microbiol Antimicrob</i>. 2017;16(1):52. doi:10.1186/s12941-017-0227-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/28738848/pubmed" id="28738848" target="_blank">28738848</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29987069">
<a name="29987069"></a>Szeto CC, Li PK. Concerns regarding inconsistencies within and between ISPD recommendations for peritonitis and catheter related infections-in reply. <i>Perit Dial Int</i>. 2018;38(4):311-312. doi:10.3747/pdi.2018.00046<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/29987069/pubmed" id="29987069" target="_blank">29987069</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12760858">
<a name="12760858"></a>Tam VH, McKinnon PS, Akins RL, Drusano GL, Rybak MJ. Pharmacokinetics and pharmacodynamics of cefepime in patients with various degrees of renal function.<i> Antimicrob Agents Chemother.</i> 2003;47(6):1853-1861. doi:10.1128/aac.47.6.1853-1861.2003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/12760858/pubmed" id="12760858" target="_blank">12760858</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34864936">
<a name="34864936"></a>Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ. Infectious Diseases Society of America guidance on the treatment of AmpC β-lactamase-producing enterobacterales, carbapenem-resistant acinetobacter baumannii, and stenotrophomonas maltophilia infections. <i>Clin Infect Dis</i>. 2022;74(12):2089-2114. doi:10.1093/cid/ciab1013<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/34864936/pubmed" id="34864936" target="_blank">34864936</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31254655">
<a name="31254655"></a>Thabit AK, Varugehese CA, Levine AR. Antibiotic use and duration in association with Clostridioides difficile infection in a tertiary academic medical center: a retrospective case-control study. <i>Anaerobe</i>. 2019;59:126-130. doi:10.1016/j.anaerobe.2019.06.016<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/31254655/pubmed" id="31254655" target="_blank">31254655</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27132188">
<a name="27132188"></a>Thompson RZ, Martin CA, Burgess DR, Rutter WC, Burgess DS. Optimizing beta-lactam pharmacodynamics against Pseudomonas aeruginosa in adult cystic fibrosis patients. <i>J Cyst Fibros</i>. 2016;15(5):660-663. doi:10.1016/j.jcf.2016.04.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/27132188/pubmed" id="27132188" target="_blank">27132188</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29046121">
<a name="29046121"></a>Tran A, O'Sullivan D, Krawczynski M. Cefepime intravenous push versus intravenous piggyback on time to administration of first-dose vancomycin in the emergency department. <i>J Pharm Pract</i>. 2018;31(6):605-609. doi:10.1177/0897190017734442<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/29046121/pubmed" id="29046121" target="_blank">29046121</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31201049">
<a name="31201049"></a>Triplett JD, Lawn ND, Chan J, Dunne JW. Cephalosporin-related neurotoxicity: metabolic encephalopathy or non-convulsive status epilepticus?. <i>J Clin Neurosci</i>. 2019;67:163-166. doi:10.1016/j.jocn.2019.05.035<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/31201049/pubmed" id="31201049" target="_blank">31201049</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16163635">
<a name="16163635"></a>Trotman RL, Williamson JC, Shoemaker DM, Salzer WL. Antibiotic dosing in critically ill adult patients receiving continuous renal replacement therapy. <i>Clin Infect Dis.</i> 2005;41(8):1159-1166.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/16163635/pubmed" id="16163635" target="_blank">16163635</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15494903">
<a name="15494903"></a>Tunkel AR, Hartman BJ, Kaplan SL, et al. Practice guidelines for the management of bacterial meningitis. <i>Clin Infect Dis.</i> 2004;39(9):1267-1284. doi:10.1086/425368<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/15494903/pubmed" id="15494903" target="_blank">15494903</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28203777">
<a name="28203777"></a>Tunkel AR, Hasbun R, Bhimraj A, et al. 2017 Infectious Diseases Society of America's clinical practice guidelines for healthcare-associated ventriculitis and meningitis. <i>Clin Infect Dis.</i> Published online February 14, 2017. doi:10.1093/cid/ciw861<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/28203777/pubmed" id="28203777" target="_blank">28203777</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27216385">
<a name="27216385"></a>Vardakas KZ, Trigkidis KK, Boukouvala E, Falagas ME. Clostridium difficile infection following systemic antibiotic administration in randomised controlled trials: a systematic review and meta-analysis. <i>Int J Antimicrob Agents</i>. 2016;48(1):1-10. doi:10.1016/j.ijantimicag.2016.03.008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/27216385/pubmed" id="27216385" target="_blank">27216385</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14969569">
<a name="14969569"></a>Veltri MA, Neu AM, Fivush BA, Parekh RS, Furth SL. Drug dosing during intermittent hemodialysis and continuous renal replacement therapy: special considerations in pediatric patients. <i>Paediatr Drugs</i>. 2004;6(1):45-65.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/14969569/pubmed" id="14969569" target="_blank">14969569</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-VON.1">
<a name="VON.1"></a>Vermont Oxford Network (VON). Neonatal drug concentrations. Updated November 2022. Accessed August 10, 2023. https://public.vtoxford.org/neonatal-drug-concentrations
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Vollmer.1">
<a name="Vollmer.1"></a>Vollmer CM Jr, Zakko SF, Afdhal NH. Treatment of acute calculous cholecystitis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed April 13, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22851742">
<a name="22851742"></a>Warady BA, Bakkaloglu S, Newland J, et al. Consensus guidelines for the prevention and treatment of catheter-related infections and peritonitis in pediatric patients receiving peritoneal dialysis: 2012 update. <i>Perit Dial Int</i>. 2012;(32)(suppl 2):S32-S86.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/22851742/pubmed" id="22851742" target="_blank">22851742</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29272341">
<a name="29272341"></a>Watson T, Hickok J, Fraker S, Korwek K, Poland RE, Septimus E. Evaluating the risk factors for hospital-onset Clostridium difficile infections in a large healthcare system. <i>Clin Infect Dis</i>. 2018;66(12):1957-1959. doi:10.1093/cid/cix1112<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/29272341/pubmed" id="29272341" target="_blank">29272341</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Weintrob.1">
<a name="Weintrob.1"></a>Weintrob AC, Sexton DJ. Clinical manifestations, diagnosis, and management of diabetic infections of the lower extremities. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 9, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.1">
<a name="WHO.1"></a>World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the eleventh WHO model list of essential drugs. http://www.who.int/maternal_child_adolescent/documents/55732/en. Published 2002.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Wingard.1">
<a name="Wingard.1"></a>Wingard JR. Treatment of neutropenic fever syndromes in adults with hematologic malignancies and hematopoietic cell transplant recipients (high-risk patients). Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 10, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Wong.1">
<a name="Wong.1"></a>Wong Kee Song LM, Marcon NE. Neutropenic enterocolitis (typhlitis). Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 10, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28077047">
<a name="28077047"></a>Wrenn RH, Cluck D, Kennedy L, Williamson JC. Extended infusion compared to standard infusion cefepime as empiric treatment of febrile neutropenia. <i>J Oncol Pharm Pract</i>. 2018;24(3):170-175. doi:10.1177/1078155216687151<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/28077047/pubmed" id="28077047" target="_blank">28077047</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8968455">
<a name="8968455"></a>Wynd MA, Paladino JA. Cefepime: A Fourth-Generation Parenteral Cephalosporin. <i>Ann Pharmacother</i>. 1996;30(12):1414-1424.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/8968455/pubmed" id="8968455" target="_blank">8968455</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30535100">
<a name="30535100"></a>Yahav D, Franceschini E, Koppel F, et al; Bacteremia Duration Study Group. Seven versus fourteen days of antibiotic therapy for uncomplicated gram-negative bacteremia: a non-inferiority randomized controlled trial. <i>Clin Infect Dis.</i> 2018. doi:10.1093/cid/ciy1054<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/30535100/pubmed" id="30535100" target="_blank">30535100</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36620795">
<a name="36620795"></a>Yang K, Moga T, Nallapeta NS, et al. Severe cholestatic drug-induced liver injury with cephalosporin use. <i>Cureus</i>. 2022;14(12):e32262. doi:10.7759/cureus.32262<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/36620795/pubmed" id="36620795" target="_blank">36620795</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25381169">
<a name="25381169"></a>Zasowski E, Bland CM, Tam VH, Lodise TP. Identification of optimal renal dosage adjustments for high-dose extended-infusion cefepime dosing regimens in hospitalized patients. <i>J Antimicrob Chemother</i>. 2015;70(3):877-881. doi:10.1093/jac/dku435<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/25381169/pubmed" id="25381169" target="_blank">25381169</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32116695">
<a name="32116695"></a>Zhao Y, Yao BF, Kou C, et al. Developmental population pharmacokinetics and dosing optimization of cefepime in neonates and young infants. <i>Front Pharmacol</i>. 2020;11:14. doi: 10.3389/fphar.2020.00014<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/32116695/pubmed" id="32116695" target="_blank">32116695</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22949297">
<a name="22949297"></a>Zobell JT, Waters CD, Young DC, et al. Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: II. cephalosporins and penicillins<i>. Pediatr Pulmonol</i>. 2013;48(2):107-122. doi:10.1002/ppul.22669<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/22949297/pubmed" id="22949297" target="_blank">22949297</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30431557">
<a name="30431557"></a>Zuppa AF, Zane NR, Moorthy G, et al. A population pharmacokinetic analysis to study the effect of extracorporeal membrane oxygenation on cefepime disposition in children. <i>Pediatr Crit Care Med</i>. 2019;20(1):62-70. doi:10.1097/PCC.0000000000001786<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefepime-pediatric-drug-information/abstract-text/30431557/pubmed" id="30431557" target="_blank">30431557</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 13126 Version 369.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
